Use of Molecular Chaperones for the Enhanced Production of Secreted, Recombinant Proteins in Mammalian Cells

Abstract

The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.

Description

CROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional application No. 60/483,505, filed Jun. 27, 2003, which is incorporated by reference in its entirety.

FIELD OF THE INVENTION

[0002] The present invention relates to the general field of recombinant protein production in a mammalian host cell. Specifically, the present invention relates to enhanced production of a secreted recombinant protein product by coexpressing at least one chaperone protein in the mammalian host cell.

BACKGROUND OF THE INVENTION

[0003] In both procaryotic and eucaryotic cells, molecular chaperone proteins catalyze disulfide bond exchange and assist in the proper folding of newly synthesized proteins. This observation has led to a large number of studies and proposed uses for these quality control proteins. For example, increasing pDI (protein disulfide isomerase) activity in bacterial, yeast and insect cell expression systems can have beneficial effects on protein solubility and folding and, in some cases, can lead to an increase in the secretion of heterologous proteins (1-7). In addition, other studies have shown that the molecular chaperones immunoglobulin heavy chain binding protein (BiP, also referred to as glucose regulated protein) and human heat shock protein 70 (Hsp 70) have a beneficial effect on recombinant protein expression in insect cell systems (5, 8-12).

[0004] Molecular chaperones have not had the same level of success on recombinant protein expression and secretion in mammalian cell systems. For example, overexpression of the pDI chaperone in Chinese hamster ovary (CHO) cells not only had no effect on the secretion levels of IL-15, but also caused a decrease in secretion, and an increase in cellular retention of a tumor necrosis factor receptor-Fc fusion protein (TNFR:Fc) (13). Other studies have shown that overexpression of the BiP chaperone in mammalian cells can lead to increased cellular retention and decreased secretion of recombinant proteins (14-15 and U.S. Pat. No. 4,912,040). The regulatory mechanisms involved in protein processing within the mammalian cell are complex, and probably involve the cooperation of many of these chaperone proteins. Therefore, one cannot predict whether a particular chaperone will lead to an increase in the production of a certain recombinant protein.

[0005] Because of the contradictory teaching in the field, the effect of chaperone proteins on the production of a secreted recombinant protein product is not understood and appreciated. U.S. Pat. No. 6,451,597 (the '597 patent) describes a method for enhanced production of viral particles, and speculates on the effect of chaperones on improving yield of a recombinant protein in eukaryotic cells. However, no actual expression of a recombinant protein is disclosed. However, other studies had found that over-expression of chaperones in eukaryotic cell lines either had no effect on product yields or had reduced secretion of recombinant proteins (14, 15). See also U.S. Pat. No. 4,912,040. In light of the contradictory teaching in the field, the '597 patent does not enable one of skill in the art to use chaperones to improve the production and secretion of a recombinant protein in eukaryotic cells. The state of art does not teach one to predict what effect a particular chaperone will have in the production and secretion of a given recombinant protein in cell culture models such as those described herein. The applicants were therefore surprised to find that when the chaperones described in this study were transfected into mammalian cell lines expressing a secreted, recombinant protein, the resultant effect was an overall increase in the production of the secreted protein.

SUMMARY OF THE INVENTION

[0006] The present invention relates to mammalian cells, methods and reagents therefor, for enhanced expression of a secreted recombinant protein product in a mammalian host cell.

[0007] In one aspect of the invention, a mammalian host cell for enhanced expression of a recombinant protein product is provided, said mammalian cell having genetic material coding for expression of said recombinant protein product and transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.

[0008] In one embodiment of the first aspect of the invention, the recombinant protein product is secreted.

[0009] In another embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.

[0010] In another embodiment of the invention, the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.

[0011] In another embodiment of the invention, the recombinant protein product comprises bikunin, Factor VIII, IL2SA, or fragment thereof.

[0012] In another embodiment of the invention, the transformation occurs with an expression vector comprising DNA encoding calnexin, calreticulin, Erp57, Hsp40, and Hsp70.

[0013] In another embodiment of the invention, the transformation occurs with a first expression vector comprising DNA encoding calreticulin and a second expression vector.

[0014] In a second aspect of the invention, a method for producing a mammalian host cell for enhanced expression of a target recombinant protein or fragment thereof is provided, wherein the method comprises providing a mammalian cell having genetic material coding for expression of a target recombinant protein or fragment thereof; and transforming the mammalian cell with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.

[0015] In one embodiment of the second aspect of the invention, the recombinant protein product is secreted.

[0016] In another embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.

[0017] In another embodiment of the invention, the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.

[0018] In another embodiment of the invention, the recombinant protein product comprises bikunin, Factor VIII, IL2SA, or fragment thereof.

[0019] In another embodiment of the invention, the transformation occurs with an expression vector comprising DNA encoding calnexin, calreticulin, Erp57, Hsp40, or Hsp70.

[0020] In another embodiment of the invention, the transformation occurs with a first expression vector comprising DNA encoding calreticulin and a second expression vector comprising DNA encoding Erp57.

[0021] In a third aspect of the invention, a method for producing a secreted recombinant protein product is provided, the method comprising the steps of: culturing a mammalian host cell, said mammalian host cell having genetic material coding for expression of said recombinant protein product and transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, hsp40, and Hsp70; and recovering from the culture medium the recombinant protein product so produced and secreted.

[0022] In one embodiment of the third aspect of the invention, the recombinant protein product is secreted.

[0023] In another embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.

[0024] In another embodiment of the invention, the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.

[0025] In another embodiment of the invention, the recombinant protein product comprises bikunin, Factor VIII, IL2SA, or fragment thereof.

[0026] In another embodiment of the invention, the transformation occurs with an expression vector comprising DNA encoding calnexin, calreticulin, Erp57, Hsp40, or Hsp70.

[0027] In another embodiment of the invention, the transformation occurs with a first expression vector comprising DNA encoding calreticulin and a second expression vector comprising DNA encoding Erp57.

[0028] In a fourth aspect of the invention, a method for enhancing yield of a recombinant protein or fragment thereof in a mammalian cell is provided, the method comprising providing a first cell line having genetic material coding for expression of said recombinant protein product or fragment thereof and introducing at least one chaperone protein expression vector into said first cell line so as to form a modified cell line; and selecting from said modified cell line at least one second cell line exhibiting enhanced yield of the recombinant protein or fragment thereof.

[0029] In one embodiment of the forth aspect of the invention, the recombinant protein product is secreted.

[0030] In another embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.

[0031] In another embodiment of the invention, the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.

[0032] In another embodiment of the invention, the recombinant protein product comprises bikunin, Factor VIII, IL2SA, or fragment thereof.

[0033] In another embodiment of the invention, the chaperone expression vector comprises DNA encoding calnexin, calreticulin, Erp57, Hsp40, or Hsp70.

[0034] In another embodiment of the invention, said introducing occurs with a first chaperone expression vector comprising DNA encoding calreticulin and a second chaperone expression vector comprising DNA encoding Erp57.

[0035] In another embodiment of the invention, at least one second cell line is produced from said first cell line by selecting a portion of said first cell line exhibiting integration of the chaperone protein expression vector into host DNA.

[0036] In a fifth aspect of the invention, a method for enhancing yield of a recombinant protein or fragment thereof in a mammalian cell is provided, the method comprises introducing genetic material coding for a recombinant protein or fragment thereof into a cell line exhibiting enhanced chaperone protein expression.

[0037] In one embodiment of this aspect of the invention, the recombinant protein product is secreted.

[0038] In another embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.

[0039] In another embodiment of the invention, the cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.

[0040] In another embodiment of the invention, the recombinant protein product comprises bikunin, Factor VIII, IL2SA, or fragment thereof.

[0041] In another embodiment of the invention, the chaperone protein comprises calnexin, calreticulin, Erp57, Hsp40, or Hsp70.

[0042] In another embodiment of the invention, the chaperone protein comprises calreticulin and Erp57.

BRIEF DESCRIPTION OF THE DRAWINGS

[0043] The invention will be better understood from a consideration of the following detailed description and claims, taken in conjunction with the drawings, in which:

[0044] FIG. 1 depicts the sequences of RT-PCR primers used to amplify cDNA of ER chaperones from a human cDNA library. Underlined indicates a built in EcoRI (5' primer) or XbaI (3' primer) restriction site. CNX: calnexin; CRT: calreticulin;

[0045] FIG. 2A depicts the complete nucleotide and amino acid sequences of calnexin cloned by RT-PCR. The 5' EcoRI and 3' XbaI sites within the primers are underlined. The start codon and stop codon are shown in bold text;

[0046] FIG. 2B depicts the complete nucleotide and amino acid sequences of calreticulin cloned by RT-PCR. The 5' EcoRI and 3' XbaI sites are underlined. The start codon and stop codon are shown in bold text;

[0047] FIG. 2c depicts the complete nucleotide and amino acid sequences of Erp57 cloned by RT-PCR. The 5' EcoRI and 3' XbaI sites are underlined. The start codon and stop codon are shown in bold text;

[0048] FIG. 2D depicts the complete nucleotide and amino acid sequences of the coding region of the human Hsp70 gene;

[0049] FIG. 2E depicts the complete nucleotide and amino acid sequences of the coding region of the human Hsp40 gene. The start codon is shown in bold and underlined text;

[0050] FIG. 2F depicts the complete nucleotide and amino acid sequences of the coding region of the glutamine synthetase gene. The start codon is shown in bold and underlined text;

[0051] FIG. 3 is an illustration of overexpression of bikunin in clones super transfected with calnexin (X4.14:5, X4/14:30), Hsp70 (7-3) or Erp57(X4/19:62). The specific Bikunin production rate for all cell lines is expressed as pg Bikunin/cell/day (SPR). Each day cells were harvested and transferred into fresh media and incubated for 24 hours at 37° C. in shaking flasks. The following day, cells were harvested again, counted and re-suspended into fresh media of the same volume and incubated similarly for another 24 hours. Bikunin activity measurements (pg/cell/day) were conducted on samples of the spent media. The same procedure was repeated every day until the cell number and viability started to decrease. The control cell line (CF 9-20) expresses bikunin but does not express any of chaperone proteins;

[0052] FIG. 4 is an illustration of overexpression of bikunin in clones super transfected with Hsp70. All clones except CF9-20 (control cells) are super transfected with Hsp70. The experiment procedure is the same as that described in FIG. 3; and

[0053] FIG. 5 depicts the amino acid sequence of bikunin.

DETAILED DESCRIPTION OF THE INVENTION

[0054] The present invention relates to a method and reagents therefor, for enhanced expression of a secreted recombinant protein product in a mammalian host cell.

[0055] In one embodiment of the invention, a mammalian host cell for enhanced expression of a recombinant protein product is provided, wherein said mammalian cell comprises genetic material coding for expression of said recombinant protein product and is further transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.

[0056] In another embodiment of the invention, the mammalian host cell is stably transformed with the genetic material coding for expression of said recombinant protein product.

[0057] The term "mammalian host cell" is used to refer to a mammalian cell which has been transfected, or is capable of being transfected with a nucleic acid sequence and then of expressing a selected gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent, so long as the selected gene is present.

[0058] Suitable mammalian cells for use in the present invention include, but are not limited to Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, human HeLa cells, monkey COS-1 cell, human embryonic kidney 293 cells, mouse myeloma NSO and human HKB cells (U.S. Pat. No. 6,136,599). The other cell lines are readily available from the ATCC.

[0059] The term "transfection" is used to refer to the uptake of foreign or exogenous DNA by a cell, and a cell has been "transfected" when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, e.g., Graham et al., 1973, Virology 52:456; Sambrook et al., Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratories, 1989); Davis et al., Basic Methods in Molecular Biology (Elsevier, 1986); and Chu et al., 1981, Gene 13:197. Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

[0060] Suitable techniques of transfection for use in the present invention include, but are not limited to calcium phosphate-mediated transfection, DEAE-dextran mediated transfection, and electroporation. Cationic lipid transfection using commercially available reagents including the Boehringer Mannheim Transfection Reagent (N->1-(2,3-Dioleoyloxy)propyl-N,N,N-trimethyl ammoniummethylsulfate, Boehringer Mannheim, Indianapolis, Ind.) or LIPOFECTIN or LIPOFECTAMIN or DMRIE reagent (GIBCO-BRL, Gaithersburg, Md.) may also be used.

[0061] As used herein the term "super transfection" refers to transfecting more than one expression vectors to a host cell already expressing a recombinant gene.

[0062] The term "transformation" as used herein refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain a new DNA. For example, a cell is transformed where it is genetically modified from its native state. Following transfection, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid. A cell is considered to have been stably transformed when the DNA is replicated with the division of the cell.

[0063] As used herein the term "modified cell line" refers to a cell line either transiently or stably transformed with one or more DNA constructs.

[0064] Polynucleotides, genetic material, recombinant DNA molecules, expression vectors, and such, used in the practice of the present invention may be isolated using standard cloning methods such as those described by Sambrook et al. (Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., 1989; which is incorporated herein by reference). Alternatively, the polynucleotides coding for a recombinant protein product of the present invention may be synthesized using standard techniques that are well known in the art, such as by synthesis on an automated DNA synthesizer. For example, in one embodiment of the invention, DNA sequences encoding the calnexin protein are synthesized by RT-PCR using primers depicted in FIG. 1.

[0065] As used herein an "expression vector" refers to a DNA molecule, or a clone of such a molecule, which has been modified through human intervention to contain segments of DNA combined and juxtaposed in a manner that would not otherwise exist in nature. DNA constructs may be engineered to include a first DNA segment encoding a polypeptide of the present invention operably linked to additional DNA segments required for the expression of the first DNA segment. Within the context of the present invention additional DNA segments will generally include promoters and transcription terminators and may further include enhancers and other elements. One or more selectable markers may also be included. DNA constructs useful for expressing cloned DNA segments in a variety of prokaryotic and eukaryotic host cells can be prepared from readily available components or purchased from commercial suppliers.

[0066] DNA constructs may also contain DNA segments necessary to direct the secretion of a polypeptide or protein of interest. Such DNA segments may include at least one secretory signal sequence. Secretory signal sequences, also called leader sequences, prepro sequences and/or pre sequences, are amino acid sequences that act to direct the secretion of mature polypeptides or proteins from a cell. Such sequences are characterized by a core of hydrophobic amino acids and are typically (but not exclusively) found at the amino termini of newly synthesized proteins. Very often the secretory peptide is cleaved from the mature protein during secretion. Such secretory peptides contain processing sites that allow cleavage of the secretory peptide from the mature protein as it passes through the secretory pathway. A recombinant protein may contain a secretory signal sequence in its original amino acid sequence, or may be engineered to become a secreted protein by inserting an engineered secretory signal sequence into its original amino acid sequence. The choice of suitable promoters, terminators and secretory signals is well within the level of ordinary skill in the art. Expression of cloned genes in cultured mammalian cells and in E. coli, for example, is discussed in detail in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., 1989; which is incorporated herein by reference).

[0067] As used herein, the term "recombinant protein product" refers to a recombinant protein or fragment thereof expressed from the genetic material introduced into the host mammalian cell.

[0068] After transfection, the cell may be maintained either transiently transformed or stably transformed with said DNA construct. Introduction of multiple DNA constructs, and selection of cells containing the multiple DNA constructs can be done either simultaneously or, more preferably, sequentially. The technique of establishing a cell line stably transformed with a genetic material or expression vector is well known in the art (Current Protocols in Molecular Biology). In general, after transfection, the growth medium will select for cells containing the DNA construct by, for example, drug selection or deficiency in an essential nutrient, which is complemented by a selectable marker on the DNA construct or co-transfected with the DNA construct. Cultured mammalian cells are generally cultured in commercially available serum-containing or serum-free medium. Selection of a medium appropriate for the particular host cell used is within the level of ordinary skill in the art.

[0069] Suitable selectable markers for drug selection used in this invention include, but are not limited to, neomycin (G418), hygromycin, puromycin, zeocin, colchine, methotrexate, and methionine sulfoximine.

[0070] Once a drug resistant cell population is established, individual clones may be selected and screened for high expressing clones. Methods of establishing cloned cell line are well known in the art, including, but not limited to, using a cloning cylinder, or by limiting dilution. Expression of the recombinant product of interest from each clone can be measured by methods such as, but not limited to, immunoassay, enzymatic assay, or chromogenic assay.

[0071] Cell line stably transformed with a first DNA construct may be then used as host cell for transfection with a second or more DNA constructs, and subjected to different drug selections.

[0072] In one embodiment of the invention, a mammalian host cell with enhanced expression and secretion of bikunin protein or fragment thereof is provided, wherein the mammalian host cell is further transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.

[0073] In a preferred embodiment of the invention, the mammalian host cell with enhanced expression and secretion of bikunin is a CHO cell.

[0074] As used herein the term "bikunin" refers to any protein, which has at least one Kunitz domain. Kunitz-type domains have been described in references such as Laskowski et al., 1980, Ann Rev Biochem. 49:593-626; and U.S. Pat. No. 5,914,315 (Jun. 22, 1999). In one preferred embodiment, the term bikunin used herein refers to the amino acid sequence shown in FIG. 5. Other bikunin proteins and fragments thereof are described in U.S. application Ser. Nos. 09/144,428, 09/974,026, 09/218,913, and 09/441,966, and PCT Application serial numbers US97/03894, published as WO 97/33996, and US99/04381, published as WO 00/37099, which are incorporated herein by reference)

[0075] In another embodiment of the invention, the invention provides a mammalian host cell with enhanced expression and secretion of Factor VIII protein or fragment thereof, and the mammalian host cell is further transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.

[0076] In one preferred embodiment, the Factor VIII protein has the sequence depicted in U.S. Pat. No. 4,965,199 (incorporated herein by reference in its entirety).

[0077] In yet another preferred embodiment, the mammalian host cell with enhanced expression and secretion of Factor VIII is a BHK cell.

[0078] In another embodiment of the invention, the invention provides a mammalian host cell with enhanced expression and secretion of IL2SA protein or fragment thereof, and the mammalian host cell is further transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.

[0079] In one preferred embodiment, the IL2SA protein has the sequence depicted in U.S. Pat. No. 6,348,192 (incorporated herein by reference in its entirety).

[0080] In yet another preferred embodiment, the mammalian host cell with enhanced expression and secretion of IL2SA is a CHO cell.

[0081] In still another embodiment of the invention, the mammalian host cell is further transformed with an expression vector encoding a glutamine synthetase protein.

[0082] The present invention also provides a method for producing a mammalian host cell for enhanced expression of a target recombinant protein or fragment thereof comprising: providing a mammalian cell having genetic material coding for expression of a target recombinant protein or fragment thereof; and transforming the mammalian cell with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.

[0083] In one embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.

[0084] In another embodiment of the invention, the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.

[0085] In one preferred embodiment of the invention, the recombinant protein product is bikunin or fragment thereof and the transformation occurs with an expression vector comprising DNA encoding calnexin, Erp57, calreticulin, or Hsp70.

[0086] In another preferred embodiment of the invention, the recombinant protein product is Factor VIII or fragment thereof and the transformation occurs with a first expression vector comprising DNA encoding calreticulin and a second expression vector comprising DNA encoding Erp57.

[0087] In another preferred embodiment of the invention, the recombinant protein product is Factor VIII or fragment thereof and the transformation occurs with an expression vector comprising DNA encoding calnexin or Hsp70.

[0088] In another preferred embodiment of the invention, the recombinant protein product is IL2SA or fragment thereof and the transformation occurs with an expression vector comprising DNA encoding Hsp70.

[0089] The present invention also provides a method for producing a secreted recombinant protein product comprising culturing a mammalian host cell, said mammalian host cell having a genetic material coding for expression of said recombinant product and further transformed with at least one expression vector comprising DNA encoding a chaperone protein elected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70; and recovering from the culture medium the bikunin protein or fragment thereof so produced and secreted.

[0090] In one embodiment of the invention, the method for producing a secreted recombinant protein product comprising culturing a mammalian host cell, wherein the mammalian host cell is stably transformed with a genetic material coding for the expression of said recombinant product.

[0091] In another embodiment of the invention, the method for producing a secreted recombinant protein product further comprises transfecting the mammalian host cell with an expression vector encoding a glutamine synthetase protein.

[0092] One embodiment of the invention provides a method of producing a bikunin protein or fragment thereof, comprising culturing a mammalian host cell expressing bikunin or fragment thereof, and at least one of the chaperone proteins selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70; and recovering from the culture medium the bikunin protein or fragment thereof so produced and secreted.

[0093] In one embodiment of the invention, a method for enhanced production of a recombinant bikunin protein in a CHO cell is provided, wherein a genetic material coding for expression of said recombinant bikunin has been previously introduced into a first CHO cell line (as described in U.S. patent application Ser. No. 09/441,654 to Chan filed Nov. 12, 1999, incorporated herein by reference), comprising the steps of: inserting at least one chaperone protein expression vector into said first CHO cell line so as to form a modified CHO cell line; and selecting from said modified CHO cell line at least one second cell exhibiting enhanced yield of the recombinant bikunin protein.

[0094] In another embodiment of the invention, the method for enhancing recombinant bikunin yield in a CHO cell line comprises introducing a genetic material for such bikunin into a CHO cell line, wherein the CHO cell line exhibits enhanced chaperone protein expression.

[0095] In yet another embodiment of the invention, a method for enhanced production of a recombinant Factor VIII protein in a BHK cells is provided, wherein a genetic material coding for expression of said recombinant Factor VIII has been previously introduced into a first BHK cell line, comprising the steps of: inserting at least one chaperone protein expression vector into said first BHK cell line so as to form a modified BHK cell line; and selecting from said modified BHK cell line at least one second cell exhibiting enhanced yield of the recombinant Factor VIII protein.

[0096] In still another embodiment of the invention, the method for enhancing recombinant Factor VIII yield in a BHK cell line comprises introducing a genetic material for such Factor VIII into a BHK cell line, wherein the BHK cell line exhibits enhanced chaperone protein expression.

[0097] The present invention also provides a method for enhanced production of a recombinant IL2SA protein into a CHO cell, wherein a genetic material coding for expression of said recombinant IL2SA has been previously introduced into a first CHO cell line, comprising the steps of: inserting at least one chaperone protein expression vector into said first CHO cell line so as to form a modified CHO cell line; and selecting from said modified CHO cell line at least one second cell exhibiting enhanced yield of the recombinant IL2SA protein.

[0098] In another embodiment of the invention, the method for enhancing recombinant IL2SA yield in a CHO cell line comprises introducing a genetic material for such IL2SA into a CHO cell line, wherein the CHO cell line exhibits enhanced chaperone protein expression.

[0099] The following examples are intended for illustration purposes only, and should not be construed as limiting the scope of the invention in any way.

EXAMPLES

Example 1

Cloning of Chaperone cDNA

[0100] All chaperone sequences were cloned from human cDNA libraries followed by verification of the nucleotide sequences. DNA sequences representing the three ER chaperones were cloned by RT-PCR from a human cDNA library. The RT-PCR primers used in these reactions were designed to amplify the entire coding region using the appropriate sequences obtained from Genbank. Each pair of 5' and 3' primers include either an EcoRI (5' primer) or XbaI (3' primer) restriction site (FIG. 1) to facilitate cloning of the PCR product into the expression vector, pCI-neo (Promega).

[0101] The PCR reactions were performed using high fidelity PFU enzyme (Stratagene). Bands of the expected size were purified, digested with EcoR I and Xba I and cloned into the similarly digested pCI-neo vector. Recombinant vectors from this step were propagated in E. Coli followed by isolation and purification of the vector sequences. The sequence inserts representing the chaperones were sequenced using primers binding just outside the multiple cloning sites of the vector as well as within the chaperone sequence. Sequencing was done using the Big Dyc terminator method on MJ Research's thermal cycler and analyzed using an ABI 310 Genetic Analyzer. The cDNA sequences of human calnexin, clareticulin and Erp57 are shown in FIGS. 2A-2C.

[0102] The full-length human Hsp70 cDNA fragment was obtained by RT-PCR using human brain polyA.sup.+ RNA (CLONTECH Cat: 6516-1) and two primers designated F-Hsp70=5'AGG GAA CCG CAT GGC CAA AG and R-Hsp70=5' GAA AGG CCCCTA ATC TAC CTC CTC A. The primer sequences of Hsp 70 were derived from the previously published sequence for the human heat shock protein (Hsp70) gene [9]. The F-Hsp70 and R-Hsp70 primers included either an EcoRI or XbaI sequence respectively. The desired PCR fragment was purified by agarose gel electrophoresis and confirmed by nucleotide sequencing. The full-length human Hsp70 cDNA fragment was then inserted into the EcoRI and XbaI cloning sites of the pCI-neo vector to form the pCI-neo-Hsp70 vector. The pCI-neo-Hsp70 vector was propagated in E. Coli followed by isolation and purification of the vector sequences. pCI-neo-Hsp70 plasmid DNA was sequenced by ABI PRISM 310 Genetic Analyzer. The sequence of human Hsp70 is shown in FIG. 2D.

Example 2

Bikunin Production is Increased in CHO Cells after Transfection of an ER Chaperone Such as Calnexin, Calreticulin, Erp57 or Hsp70

[0103] A CHO cell line secreting the Bikunin recombinant protein (U.S. patent application Ser. No. 09/441,654, incorporated herein by reference) was super transfected with various combinations of the ER chaperones, calnexin (CNX), calreticulin (CRT), ERp57 or Hsp70 followed by selection with G418. Populations were obtained and screened by kallikrein assay (U.S. patent application Ser. No. 09/441,654, incorporated herein by reference). Briefly, bikunin standarts or culture fluid was serially diluted and incubated with an equal volume of kallikrein at 37° C. for 30 minutes, after which a chromogenic substrate, N-benzoyl-Pro-Phe-Arg-pNA, was added. The reaction was incubated for 15 minutes before the addition of 50% acetic acid. The amount of p-nitroanilide released was measured at 405 nM. Populations showing the highest Bikunin titers were then single cell cloned and growth expanded over a period of several weeks. Clones showing consistently higher Bikunin titers (2-4×) relative to the control CF9-20 cells were retained and expanded into shake flasks for further analysis. These clones were further narrowed based on Bikunin titers and growth characteristics demonstrated while growing in the shake flask environment. Final candidate clones were selected after several rounds and extensive analyses at the shake flask stage.

[0104] The specific Bikunin production rate for all cell lines is expressed as pg Bikunin/cell/day (SPR). Each day cells were harvested and transferred into fresh media and incubated for 24 hours at 37° C. in shaking flasks. The following day, cells were harvested again, counted and re-suspended into fresh media of the same volume and incubated similarly for another 24 hours. Bikunin activity measurements (pg/cell/day) were conducted on samples of the spent media. The same procedure was repeated every day until the cell number and viability started to decrease.

[0105] The effect of chaperone proteins on bikunin expression is shown in FIGS. 3 and 4. The control cell line (CF9-20) expresses Bikunin but does not express any of chaperone proteins. The effect of calnexin, calreticulin, and Erp57 on bikunin expression is further summarized in Table 1.

TABLE-US-00001 TABLE 1 Overall Bikunin production levels are 2-4 fold higher in clones that have been super transfected with a chaperone Clone Bikunin Increase Relative to Control Chaperone X4/14:5 2-4 CNX X4/14:30 2-4 CNX X4/19:62 2-4 ERp57 T4/13:22 1.5-2 CRT

Fold activity measurements are relative to a control cell line that expresses Bikunin but does not express any of the chaperone proteins. Cells were grown in serum free media in shake flask cultures.

Example 3

Recombinant Factor VIII Production is Increased in BHK Cells after Transfection with ER Chaperones

[0106] Stable Factor VIII producing cells (MWCB1) (U.S. Pat. No. 4,965,199; ATCC No. CRL 8544) were transfected with chaperone expression vectors in addition to pPUR, a vector containing puromycin-resistant gene, in a 10:1 ratio. Approximately 4×10⁶ MWCB1 cells were transfected with a total of 5 μg of DNA using the DMRIE-C reagent and OPTI-MEM medium (Life Technology, MD) in 6-well plates. Three days post transfection, 100,000 cells were seeded in 6-well plates and then selected in the presence of 1-2 μg/ml puromycin with OPTI-MEM medium containing 2% FBS for 2 weeks. Puromycin resistant colonies were manually picked and seeded into 96 well plates and expanded without the presence of drug. Individual clonal populations were screened for Factor VIII production using a COATEST kit (Chromogenix, Italy) according to manufacturer's instructions. The high producing clones were sequentially expanded from the 6 well dish, to T75 flask, followed by shake flask stage for stability and productivity tests. The Calnexin (CNX), Calreticulin (CRT), Erp57, Hsp40 and Hsp70 chaperones were then transfected into cells individually or in combinations of two. A significant 2 to 3 fold increase of productivity of Factor VIII was observed in clones transfected with CNX, CRT and Erp57, Hsp70, and Hsp40 while the empty vector control (PCI-Neo) showed no difference compared to the parent MWCB1 cells (Table 2).

TABLE-US-00002 TABLE 2 Recombinant Factor VIII productivity in clones Factor VIII (U/ml) Fold of Inc (SPR) MWCB1(27000JC) 0.11 1.00 PCI-Neo + pPUR 0.09 1.00 CNX + pPUR 0.31 2.88 CRT + pPUR 0.13 1.25 Erp57 + pPUR 0.05 0.91 CRT, Erp57 + pPUR 0.29 2.50 Hsp70 + pPUR 0.37 2.50 Hsp40 + pPUR 0.11 1.00 Hsp70, 40 + pPUR 0.28 1.66

Cells were seeded at 1×10⁶ per ml, total 15 ml in shake flask 2-day

Example 4

Co-Expression of BiP and PDI does not Enhance the Expression of Factor VIII and Anti-TNF Antibody in BHK and CHO Cells

[0107] Recombinant CHO cells (as described in Example 2) expressing high levels of bikunin, and recombinant BHK cells (as described in Example 3) expressing high levels of recombinant Factor VIII (rFVIII) were super-transfected with pHyg (plasmid conferring hygromycin resistance) and pBiP. The transfection conditions and selection conditions were same as in Example 2. After selection in hygromycin and limiting dilution cloning, clones were evaluated for productivity for bikunin and rFVIII activity. No significant difference in the specific productivity of clones derived from cells transfected only with the control vector (pHyg) and clones derived from cells transfected with pBiP.

Example 5

Transfection of IL2SA-Producing Clone with Glutamine Synthetase (GS) and Hsp70

[0108] IL2SA (IL2 selective agonist; U.S. Pat. No. 6,348,192, included herein by reference in its entirety) producing CHO cell line, 49-19-H42 (a clonal variant of ATCC deposit PTA-8), was co-transfected with PCI-GS and PCI-neo-Hsp70. 4×10⁶ cells were transfected with 2.5 μg of plasmid DNA using DMRIE-C reagents and OPTI-MEM medium (Life Technology, MD) in 6-well plates according to manufacturer's instructions. Three days after transfection, cells were seeded in 150-mm and 96 well plates and then selected in the presence of 10 μM MSX (methionine sulfoxinmine) and 250 μg/ml G418 with DME:F12 (1:1) medium deficient in glutamine containing 2% dialyzed FBS for 2 weeks. Single cell colonies were picked and re-seeded in 96 wells. The clones were selected for another week with increased concentrations of MSX (20 μM) and G418 (400 μg/ml). A pool is generated from a 150-mm plate after 3 weeks' selection. The pool and clones were gradually expanded to shake flasks and screened for IL2 productivity using ELISA. The expression of GS and Hsp70 proteins were confirmed by FACS analysis using a flow cytometer. The "Gpositive" cells were cultured in a glutamine-free medium supplement with 5.6 mM glutamate and 4 g/L glucose. The doubling time of these clones varied from 24 to 48 hr. A comparison of the productivity of the parent and clones is shown in Table 3. A 2-4 fold increase in overall titer and a 2-3 fold increase in specific productivity was observed in all the single cell clones when compared against either the pool or the parental line.

TABLE-US-00003 TABLE 3 Productivity of IL2SA producing cells Cell Titer density SPR (μg/ml) (10⁶/ml) (pg/c/d) GS Hsp70 49-19H42 parent line 18.78 3.51 2.67 (-) (-) 49-19H42 GShsp70-SC#12 33.87 2.63 6.44 +++ +++ 49-19H42 GShsp70-SC#14 22.08 1.83 6.03 +++ +++ 49-19H42 GShsp70-SC#17 64.00 3.05 10.50 +++ +++ 49-19H42 GShsp70-pool 10.59 1.74 3.04 +++ + +++ = all cells expressed GS or Hsp70; + = 30% of cells expressed GS or Hsp70; (-) = no expression.

Cells were seeded at 1 million per ml at day 0 in 15 ml of complete (for the parental line) or glutamine-free medium. Samples were taken at 2 day after seeding and analyzed using ELISA. For GS and Hsp70 expression, cells were fixed with 70% EtOH, labeled with proper antibodies, and analyzed by FACS.

REFERENCES

[0109] (1) Wunderlich, M.; Glockshuber, R. In vivo control of redox potential during protein folding catalyzed by bacterial protein disulfide-isomerase (DsbA). J. Biol. Chem. 1993, 268, 24547-24550.

[0110] (2) Glockshuber, R.; Wunderlich, M.; Skerra, A.; Rudolph, R. Increasing the yield of disulfide-bridged heterologous proteins secreted from transgenic microorganisms. Eur. Pat. No. 92-106978 920423 1995.

[0111] (3) Tuite, M. F.; Freedman, R. B.; Schultz, L. D.; Ellis, R. W.; Markus, H. Z.; Montgomery, D. L. Method for increasing production of disulfide bonded recombinant proteins by saccharomyces cerevisiae. Aust. Pat. No. AU679448B2 1997.

[0112] (4) Ostermeier, M.; De Sutter, K.; Georgiou, G. Eukaryotic protein disulfide isomerase complements Escherichia coli dsbA mutants and increases the yield of a heterologous secreted protein with disulfide bonds. J. Biol. Chem. 1996, 271, 10616-10622.

[0113] (5) Shusta, E. V.; Raines, R. T.; Pluckthun, A.; Wittrup, K. D. Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments. Nat. Bio-technol. 1998, 16, 773-777.

[0114] (6) Robinson, A. S.; Hines, V.; Wittrup, K. D. Protein disulfide isomerase overexpression increases secretion of foreign proteins in Saccharomyces cerevisiae. Biotechnology (N.Y.) 1994, 12, 381-384.

[0115] (7) Dunn, A.; Luz, J. M.; Natalia, D.; Gamble, J. A.; Freedman, R. B.; Tuite, M. F. Protein disulphide isomerase (PDI) is required for the secretion of a native disulphide-bonded protein from Saccharomyces cerevisiae. Biochem. Soc. Trans. 1995, 23, 78S.

[0116] (8) Hsu, T. A.; Watson, S.; Eiden, J. J.; Betenbaugh, M. J. Rescue of immunoglobulins from insolubility is facilitated by PDI in the baculovirus expression system. Protein Expr. Purif. 1996, 7, 281-288.

[0117] (9) Hsu, T. A.; Betenbaugh, M. J. Co-expression of molecular chaperone BiP improves immunoglobulin solubility and IgG secretion from Trichoplusia in insect cells. Biotechnol. Prog. 1997, 13, 96-104.

[0118] (10) Hsu, T. A.; Eiden, J. J.; Bourgarel, P.; Meo, T.; Betenbaugh, M. J. Effects of co-expressing chaperone BiP on functional antibody production in the baculovirus system. Protein Expr. Purif. 1994, 5, 595-603.

[0119] (11) Ailor, E.; Betenbaugh, M. J. Overexpression of a cytosolic chaperone to improve solubility and secretion of a recombinant IgG protein in insect cells. Biotechnol. Bioeng. 1998, 58, 196-203.

[0120] (12) Ailor, E.; Betenbaugh, M. J. Modifying secretion and post-translational processing in insect cells. Curr. Opin. Biotechnol. 1999, 10, 142-145.

[0121] (13) Davis, R., Schooley, K., Rasmussen, B., Thomas, J., Reddy, P. Effect of PDI Overexpression on Recombinant Protein Secretion in CHO Cells. Biotechnol. Prog. 2000, 16, 736-743.

[0122] (14) Domer, A. J.; Wasley, L. C.; Raney, P.; Haugejorden, S.; Green, M.; Kaufman, R. J. The stress response in Chinese hamster ovary cells. Regulation of ERp72 and protein disulfide isomerase expression and secretion. J. Biol. Chem. 1990, 265, 22029-22034.

[0123] (15) Dorner, A. J.; Wasley, L. C.; Kaufman, R. J. Overexpression of GRP78 mitigates stress induction of glucose regulated proteins and blocks secretion of selective proteins in Chinese hamster ovary cells. EMBO J. 1992, 11, 1563-1571.

[0124] (16) Current Protocols in Molecular Biology, 2003, John Wiley & Sons, Inc.

Sequence CWU 1

1

22128DNAArtificial sequencesynthetic oligonucleotide 1atgaattccg ggaggctaga gatcatgg 28228DNAArtificial sequencesynthetic oligonucleotide 2attctagatg caggggagga gggagaag 28328DNAArtificial sequencesynthetic oligonucleotide 3atgaattccc gccatgctgc tatccgtg 28428DNAArtificial sequencesynthetic oligonucleotide 4attctagact ggaggcaggc ctctctac 28528DNAArtificial sequencesynthetic oligonucleotide 5atgaattcct ccgcagtccc agccgagc 28628DNAArtificial sequencesynthetic oligonucleotide 6attctagact ctcggccctg agaggtaa 2871856DNAHomo sapiensCDS(23)..(1801) 7gaattccggg aggctagaga tc atg gaa ggg aag tgg ttg ctg tgt atg tta 52 Met Glu Gly Lys Trp Leu Leu Cys Met Leu 1 5 10ctg gtg ctt gga act gct att gtt gag gct cat gat gga cat gat gat 100Leu Val Leu Gly Thr Ala Ile Val Glu Ala His Asp Gly His Asp Asp 15 20 25gat gtg att gat att gag gat gac ctt gac gat gtc att gaa gag gta 148Asp Val Ile Asp Ile Glu Asp Asp Leu Asp Asp Val Ile Glu Glu Val 30 35 40gaa gac tca aaa cca gat acc act gct cct cct tca tct ccc aag gtt 196Glu Asp Ser Lys Pro Asp Thr Thr Ala Pro Pro Ser Ser Pro Lys Val 45 50 55act tac aaa gct cca gtt cca aca ggg gaa gta tat ttt gct gat tct 244Thr Tyr Lys Ala Pro Val Pro Thr Gly Glu Val Tyr Phe Ala Asp Ser 60 65 70ttt gac aga gga act ctg tca ggg tgg att tta tcc aaa gcc aag aaa 292Phe Asp Arg Gly Thr Leu Ser Gly Trp Ile Leu Ser Lys Ala Lys Lys75 80 85 90gac gat acc gat gat gaa att gcc aaa tat gat gga aag tgg gag gta 340Asp Asp Thr Asp Asp Glu Ile Ala Lys Tyr Asp Gly Lys Trp Glu Val 95 100 105gag gaa atg aag gag tca aag ctt cca ggt gat aaa gga ctt gtg ttg 388Glu Glu Met Lys Glu Ser Lys Leu Pro Gly Asp Lys Gly Leu Val Leu 110 115 120atg tct cgg gcc aag cat cat gcc atc tct gct aaa ctg aac aag ccc 436Met Ser Arg Ala Lys His His Ala Ile Ser Ala Lys Leu Asn Lys Pro 125 130 135ttc ctg ttt gac acc aag cct ctc att gtt cag tat gag gtt aat ttc 484Phe Leu Phe Asp Thr Lys Pro Leu Ile Val Gln Tyr Glu Val Asn Phe 140 145 150caa aat gga ata gaa tgt ggt ggt gcc tat gtg aaa ctg ctt tct aaa 532Gln Asn Gly Ile Glu Cys Gly Gly Ala Tyr Val Lys Leu Leu Ser Lys155 160 165 170aca cca gaa ctc aac ctg gat cag ttc cat gac aag acc cct tat acg 580Thr Pro Glu Leu Asn Leu Asp Gln Phe His Asp Lys Thr Pro Tyr Thr 175 180 185att atg ttt ggt cca gat aaa tgt gga gag gac tat aaa ctg cac ttc 628Ile Met Phe Gly Pro Asp Lys Cys Gly Glu Asp Tyr Lys Leu His Phe 190 195 200atc ttc cga cac aaa aac ccc aaa acg ggt atc tat gaa gaa aaa cat 676Ile Phe Arg His Lys Asn Pro Lys Thr Gly Ile Tyr Glu Glu Lys His 205 210 215gct aag agg cca gat gca gat ctg aag acc tat ttt act gat aag aaa 724Ala Lys Arg Pro Asp Ala Asp Leu Lys Thr Tyr Phe Thr Asp Lys Lys 220 225 230aca cat ctt tac aca cta atc ttg aat cca gat aat agt ttt gaa ata 772Thr His Leu Tyr Thr Leu Ile Leu Asn Pro Asp Asn Ser Phe Glu Ile235 240 245 250ctg gtt gac caa tct gtg gtg aat agt gga aat ctg ctc aat gac atg 820Leu Val Asp Gln Ser Val Val Asn Ser Gly Asn Leu Leu Asn Asp Met 255 260 265act cct cct gta aat cct tca cgt gaa att gag gac cca gaa gac cgg 868Thr Pro Pro Val Asn Pro Ser Arg Glu Ile Glu Asp Pro Glu Asp Arg 270 275 280aag ccc gag gat tgg gat gaa aga cca aaa atc cca gat cca gaa gct 916Lys Pro Glu Asp Trp Asp Glu Arg Pro Lys Ile Pro Asp Pro Glu Ala 285 290 295gtc aag cca gat gac tgg gat gaa gat gcc cct gct aag att cca gat 964Val Lys Pro Asp Asp Trp Asp Glu Asp Ala Pro Ala Lys Ile Pro Asp 300 305 310gaa gag gcc aca aaa ccc gaa ggc tgg tta gat gat gag cct gag tac 1012Glu Glu Ala Thr Lys Pro Glu Gly Trp Leu Asp Asp Glu Pro Glu Tyr315 320 325 330gta cct gat cca gac gca gag aaa cct gag gat tgg gat gaa gac atg 1060Val Pro Asp Pro Asp Ala Glu Lys Pro Glu Asp Trp Asp Glu Asp Met 335 340 345gat gga gaa tgg gag gct cct cag att gcc aac cct aga tgt gag tca 1108Asp Gly Glu Trp Glu Ala Pro Gln Ile Ala Asn Pro Arg Cys Glu Ser 350 355 360gct cct gga tgt ggt gtc tgg cag cga cct gtg att gac aac ccc aat 1156Ala Pro Gly Cys Gly Val Trp Gln Arg Pro Val Ile Asp Asn Pro Asn 365 370 375tat aaa ggc aaa tgg aag cct cct atg att gac aat ccc agt tac cag 1204Tyr Lys Gly Lys Trp Lys Pro Pro Met Ile Asp Asn Pro Ser Tyr Gln 380 385 390gga atc tgg aaa ccc agg aaa ata cca aat cca gat ttc ttt gaa gat 1252Gly Ile Trp Lys Pro Arg Lys Ile Pro Asn Pro Asp Phe Phe Glu Asp395 400 405 410ctg gaa cct ttc aga atg act cct ttt agt gct att ggt ttg gag ctg 1300Leu Glu Pro Phe Arg Met Thr Pro Phe Ser Ala Ile Gly Leu Glu Leu 415 420 425tgg tcc atg acc tct gac att ttt ttt gac aac ttt atc att tgt gct 1348Trp Ser Met Thr Ser Asp Ile Phe Phe Asp Asn Phe Ile Ile Cys Ala 430 435 440gat cga aga ata gtt gat gat tgg gcc aat gat gga tgg ggc ctg aag 1396Asp Arg Arg Ile Val Asp Asp Trp Ala Asn Asp Gly Trp Gly Leu Lys 445 450 455aaa gct gct gat ggg gct gct gag cca ggc gtt gtg ggg cag atg atc 1444Lys Ala Ala Asp Gly Ala Ala Glu Pro Gly Val Val Gly Gln Met Ile 460 465 470gag gca gct gaa gag cgc ccg tgg ctg tgg gta gtc tat att cta act 1492Glu Ala Ala Glu Glu Arg Pro Trp Leu Trp Val Val Tyr Ile Leu Thr475 480 485 490gta gcc ctt cct gtg ttc ctg gtt atc ctc ttc tgc tgt tct gga aag 1540Val Ala Leu Pro Val Phe Leu Val Ile Leu Phe Cys Cys Ser Gly Lys 495 500 505aaa cag acc agt ggt atg gag tat aag aaa act gat gca cct caa ccg 1588Lys Gln Thr Ser Gly Met Glu Tyr Lys Lys Thr Asp Ala Pro Gln Pro 510 515 520gat gtg aag gaa gag gaa gaa gag aag gaa gag gaa aag gac aag gga 1636Asp Val Lys Glu Glu Glu Glu Glu Lys Glu Glu Glu Lys Asp Lys Gly 525 530 535gat gag gag gag gaa gga gaa gag aaa ctt gaa gag aaa cag aaa agt 1684Asp Glu Glu Glu Glu Gly Glu Glu Lys Leu Glu Glu Lys Gln Lys Ser 540 545 550gat gct gaa gaa gat ggt ggc act gtc agt caa gag gag gaa gac aga 1732Asp Ala Glu Glu Asp Gly Gly Thr Val Ser Gln Glu Glu Glu Asp Arg555 560 565 570aaa cct aaa gca gag gag gat gaa att ttg aac aga tca cca aga aac 1780Lys Pro Lys Ala Glu Glu Asp Glu Ile Leu Asn Arg Ser Pro Arg Asn 575 580 585aga aag cca cga aga gag tga aacaatctta agagcttgat ctgtgatttc 1831Arg Lys Pro Arg Arg Glu 590ttctccctcc tcccctgcat ctaga 18568592PRTHomo sapiens 8Met Glu Gly Lys Trp Leu Leu Cys Met Leu Leu Val Leu Gly Thr Ala1 5 10 15Ile Val Glu Ala His Asp Gly His Asp Asp Asp Val Ile Asp Ile Glu 20 25 30Asp Asp Leu Asp Asp Val Ile Glu Glu Val Glu Asp Ser Lys Pro Asp 35 40 45Thr Thr Ala Pro Pro Ser Ser Pro Lys Val Thr Tyr Lys Ala Pro Val 50 55 60Pro Thr Gly Glu Val Tyr Phe Ala Asp Ser Phe Asp Arg Gly Thr Leu65 70 75 80Ser Gly Trp Ile Leu Ser Lys Ala Lys Lys Asp Asp Thr Asp Asp Glu 85 90 95Ile Ala Lys Tyr Asp Gly Lys Trp Glu Val Glu Glu Met Lys Glu Ser 100 105 110Lys Leu Pro Gly Asp Lys Gly Leu Val Leu Met Ser Arg Ala Lys His 115 120 125His Ala Ile Ser Ala Lys Leu Asn Lys Pro Phe Leu Phe Asp Thr Lys 130 135 140Pro Leu Ile Val Gln Tyr Glu Val Asn Phe Gln Asn Gly Ile Glu Cys145 150 155 160Gly Gly Ala Tyr Val Lys Leu Leu Ser Lys Thr Pro Glu Leu Asn Leu 165 170 175Asp Gln Phe His Asp Lys Thr Pro Tyr Thr Ile Met Phe Gly Pro Asp 180 185 190Lys Cys Gly Glu Asp Tyr Lys Leu His Phe Ile Phe Arg His Lys Asn 195 200 205Pro Lys Thr Gly Ile Tyr Glu Glu Lys His Ala Lys Arg Pro Asp Ala 210 215 220Asp Leu Lys Thr Tyr Phe Thr Asp Lys Lys Thr His Leu Tyr Thr Leu225 230 235 240Ile Leu Asn Pro Asp Asn Ser Phe Glu Ile Leu Val Asp Gln Ser Val 245 250 255Val Asn Ser Gly Asn Leu Leu Asn Asp Met Thr Pro Pro Val Asn Pro 260 265 270Ser Arg Glu Ile Glu Asp Pro Glu Asp Arg Lys Pro Glu Asp Trp Asp 275 280 285Glu Arg Pro Lys Ile Pro Asp Pro Glu Ala Val Lys Pro Asp Asp Trp 290 295 300Asp Glu Asp Ala Pro Ala Lys Ile Pro Asp Glu Glu Ala Thr Lys Pro305 310 315 320Glu Gly Trp Leu Asp Asp Glu Pro Glu Tyr Val Pro Asp Pro Asp Ala 325 330 335Glu Lys Pro Glu Asp Trp Asp Glu Asp Met Asp Gly Glu Trp Glu Ala 340 345 350Pro Gln Ile Ala Asn Pro Arg Cys Glu Ser Ala Pro Gly Cys Gly Val 355 360 365Trp Gln Arg Pro Val Ile Asp Asn Pro Asn Tyr Lys Gly Lys Trp Lys 370 375 380Pro Pro Met Ile Asp Asn Pro Ser Tyr Gln Gly Ile Trp Lys Pro Arg385 390 395 400Lys Ile Pro Asn Pro Asp Phe Phe Glu Asp Leu Glu Pro Phe Arg Met 405 410 415Thr Pro Phe Ser Ala Ile Gly Leu Glu Leu Trp Ser Met Thr Ser Asp 420 425 430Ile Phe Phe Asp Asn Phe Ile Ile Cys Ala Asp Arg Arg Ile Val Asp 435 440 445Asp Trp Ala Asn Asp Gly Trp Gly Leu Lys Lys Ala Ala Asp Gly Ala 450 455 460Ala Glu Pro Gly Val Val Gly Gln Met Ile Glu Ala Ala Glu Glu Arg465 470 475 480Pro Trp Leu Trp Val Val Tyr Ile Leu Thr Val Ala Leu Pro Val Phe 485 490 495Leu Val Ile Leu Phe Cys Cys Ser Gly Lys Lys Gln Thr Ser Gly Met 500 505 510Glu Tyr Lys Lys Thr Asp Ala Pro Gln Pro Asp Val Lys Glu Glu Glu 515 520 525Glu Glu Lys Glu Glu Glu Lys Asp Lys Gly Asp Glu Glu Glu Glu Gly 530 535 540Glu Glu Lys Leu Glu Glu Lys Gln Lys Ser Asp Ala Glu Glu Asp Gly545 550 555 560Gly Thr Val Ser Gln Glu Glu Glu Asp Arg Lys Pro Lys Ala Glu Glu 565 570 575Asp Glu Ile Leu Asn Arg Ser Pro Arg Asn Arg Lys Pro Arg Arg Glu 580 585 59091287DNAHomo sapiensCDS(12)..(1265) 9gaattcccgc c atg ctg cta tcc gtg ccg ctg ctg ctc ggc ctc ctc ggc 50 Met Leu Leu Ser Val Pro Leu Leu Leu Gly Leu Leu Gly 1 5 10ctg gcc gtc gcc gag cct gcc gtc tac ttc aag gag cag ttt ctg gac 98Leu Ala Val Ala Glu Pro Ala Val Tyr Phe Lys Glu Gln Phe Leu Asp 15 20 25gga gac ggg tgg act tcc cgc tgg atc gaa tcc aaa cac aag tca gat 146Gly Asp Gly Trp Thr Ser Arg Trp Ile Glu Ser Lys His Lys Ser Asp30 35 40 45ttt ggc aaa ttc gtt ctc agt tcc ggc aag ttc tac ggt gac gag gag 194Phe Gly Lys Phe Val Leu Ser Ser Gly Lys Phe Tyr Gly Asp Glu Glu 50 55 60aaa gat aaa ggt ttg cag aca agc cag gat gca cgc ttt tat gct ctg 242Lys Asp Lys Gly Leu Gln Thr Ser Gln Asp Ala Arg Phe Tyr Ala Leu 65 70 75tcg gcc agt ttc gag cct ttc agc aac aaa ggc cag acg ctg gtg gtg 290Ser Ala Ser Phe Glu Pro Phe Ser Asn Lys Gly Gln Thr Leu Val Val 80 85 90cag ttc acg gtg aaa cat gag cag aac atc gac tgt ggg ggc ggc tat 338Gln Phe Thr Val Lys His Glu Gln Asn Ile Asp Cys Gly Gly Gly Tyr 95 100 105gtg aag ctg ttt cct aat agt ttg gac cag aca gac atg cac gga gac 386Val Lys Leu Phe Pro Asn Ser Leu Asp Gln Thr Asp Met His Gly Asp110 115 120 125tca gaa tac aac atc atg ttt ggt ccc gac atc tgt ggc cct ggc acc 434Ser Glu Tyr Asn Ile Met Phe Gly Pro Asp Ile Cys Gly Pro Gly Thr 130 135 140aag aag gtt cat gtc atc ttc aac tac aag ggc aag aac gtg ctg atc 482Lys Lys Val His Val Ile Phe Asn Tyr Lys Gly Lys Asn Val Leu Ile 145 150 155aac aag gac atc cgt tgc aag gat gat gag ttt aca cac ctg tac aca 530Asn Lys Asp Ile Arg Cys Lys Asp Asp Glu Phe Thr His Leu Tyr Thr 160 165 170ctg att gtg cgg cca gac aac acc tat gag gtg aag att gac aac agc 578Leu Ile Val Arg Pro Asp Asn Thr Tyr Glu Val Lys Ile Asp Asn Ser 175 180 185cag gtg gag tcc ggc tcc ttg gaa gac gat tgg gac ttc ctg cca ccc 626Gln Val Glu Ser Gly Ser Leu Glu Asp Asp Trp Asp Phe Leu Pro Pro190 195 200 205aag aag ata aag gat cct gat gct tca aaa ccg gaa gac tgg gat gag 674Lys Lys Ile Lys Asp Pro Asp Ala Ser Lys Pro Glu Asp Trp Asp Glu 210 215 220cgg gcc aag atc gat gat ccc aca gac tcc aag cct gag gac tgg gac 722Arg Ala Lys Ile Asp Asp Pro Thr Asp Ser Lys Pro Glu Asp Trp Asp 225 230 235aag ccc gag cat atc cct gac cct gat gct aag aag ccc gag gac tgg 770Lys Pro Glu His Ile Pro Asp Pro Asp Ala Lys Lys Pro Glu Asp Trp 240 245 250gat gaa gag atg gac gga gag tgg gaa ccc cca gtg att cag aac cct 818Asp Glu Glu Met Asp Gly Glu Trp Glu Pro Pro Val Ile Gln Asn Pro 255 260 265gag tac aag ggt gag tgg aag ccc cgg cag atc gac aac cca gat tac 866Glu Tyr Lys Gly Glu Trp Lys Pro Arg Gln Ile Asp Asn Pro Asp Tyr270 275 280 285aag ggc act tgg atc cac cca gaa att gac aac ccc gag tat tct ccc 914Lys Gly Thr Trp Ile His Pro Glu Ile Asp Asn Pro Glu Tyr Ser Pro 290 295 300gat ccc agt atc tat gcc tat gat aac ttt ggc gtg ctg ggc ctg gac 962Asp Pro Ser Ile Tyr Ala Tyr Asp Asn Phe Gly Val Leu Gly Leu Asp 305 310 315ctc tgg cag gtc aag tct ggc acc atc ttt gac aac ttc ctc atc acc 1010Leu Trp Gln Val Lys Ser Gly Thr Ile Phe Asp Asn Phe Leu Ile Thr 320 325 330aac gat gag gca tac gct gag gag ttt ggc aac gag acg tgg ggc gta 1058Asn Asp Glu Ala Tyr Ala Glu Glu Phe Gly Asn Glu Thr Trp Gly Val 335 340 345aca aag gca gca gag aaa caa atg aag gac aaa cag gac gag gag cag 1106Thr Lys Ala Ala Glu Lys Gln Met Lys Asp Lys Gln Asp Glu Glu Gln350 355 360 365agg ctt aag gag gag gaa gaa gac aag aaa cgc aaa gag gag gag gag 1154Arg Leu Lys Glu Glu Glu Glu Asp Lys Lys Arg Lys Glu Glu Glu Glu 370 375 380gca gag gac aag gag gat gat gag gac aaa gat gag gat gag gag gat 1202Ala Glu Asp Lys Glu Asp Asp Glu Asp Lys Asp Glu Asp Glu Glu Asp 385 390 395gag gag gac aag gag gaa gat gag gag gaa gat gtc ccc ggc cag gcc 1250Glu Glu Asp Lys Glu Glu Asp Glu Glu Glu Asp Val Pro Gly Gln Ala 400 405 410aag gac gag ctg tag agaggcctgc ctccagtcta ga 1287Lys Asp Glu Leu 41510417PRTHomo sapiens 10Met Leu Leu Ser Val Pro Leu Leu Leu Gly Leu Leu Gly Leu Ala Val1 5 10 15Ala Glu Pro Ala Val Tyr Phe Lys Glu Gln Phe Leu Asp Gly Asp Gly 20 25 30Trp Thr Ser Arg Trp Ile Glu Ser Lys His Lys Ser Asp Phe Gly Lys 35 40 45Phe Val Leu Ser Ser Gly Lys Phe Tyr Gly Asp Glu Glu Lys Asp Lys 50 55 60Gly Leu Gln Thr Ser Gln Asp Ala Arg Phe Tyr Ala Leu Ser Ala Ser65 70 75 80Phe Glu Pro Phe Ser Asn Lys Gly Gln Thr Leu Val Val Gln Phe Thr 85 90

95Val Lys His Glu Gln Asn Ile Asp Cys Gly Gly Gly Tyr Val Lys Leu 100 105 110Phe Pro Asn Ser Leu Asp Gln Thr Asp Met His Gly Asp Ser Glu Tyr 115 120 125Asn Ile Met Phe Gly Pro Asp Ile Cys Gly Pro Gly Thr Lys Lys Val 130 135 140His Val Ile Phe Asn Tyr Lys Gly Lys Asn Val Leu Ile Asn Lys Asp145 150 155 160Ile Arg Cys Lys Asp Asp Glu Phe Thr His Leu Tyr Thr Leu Ile Val 165 170 175Arg Pro Asp Asn Thr Tyr Glu Val Lys Ile Asp Asn Ser Gln Val Glu 180 185 190Ser Gly Ser Leu Glu Asp Asp Trp Asp Phe Leu Pro Pro Lys Lys Ile 195 200 205Lys Asp Pro Asp Ala Ser Lys Pro Glu Asp Trp Asp Glu Arg Ala Lys 210 215 220Ile Asp Asp Pro Thr Asp Ser Lys Pro Glu Asp Trp Asp Lys Pro Glu225 230 235 240His Ile Pro Asp Pro Asp Ala Lys Lys Pro Glu Asp Trp Asp Glu Glu 245 250 255Met Asp Gly Glu Trp Glu Pro Pro Val Ile Gln Asn Pro Glu Tyr Lys 260 265 270Gly Glu Trp Lys Pro Arg Gln Ile Asp Asn Pro Asp Tyr Lys Gly Thr 275 280 285Trp Ile His Pro Glu Ile Asp Asn Pro Glu Tyr Ser Pro Asp Pro Ser 290 295 300Ile Tyr Ala Tyr Asp Asn Phe Gly Val Leu Gly Leu Asp Leu Trp Gln305 310 315 320Val Lys Ser Gly Thr Ile Phe Asp Asn Phe Leu Ile Thr Asn Asp Glu 325 330 335Ala Tyr Ala Glu Glu Phe Gly Asn Glu Thr Trp Gly Val Thr Lys Ala 340 345 350Ala Glu Lys Gln Met Lys Asp Lys Gln Asp Glu Glu Gln Arg Leu Lys 355 360 365Glu Glu Glu Glu Asp Lys Lys Arg Lys Glu Glu Glu Glu Ala Glu Asp 370 375 380Lys Glu Asp Asp Glu Asp Lys Asp Glu Asp Glu Glu Asp Glu Glu Asp385 390 395 400Lys Glu Glu Asp Glu Glu Glu Asp Val Pro Gly Gln Ala Lys Asp Glu 405 410 415Leu111696DNAHomo sapiensCDS(65)..(1582) 11gaattcctcc gcagtcccag ccgagccgcg acccttccgg ccgtccccac cccacctcgc 60cgcc atg cgc ctc cgc cgc cta gcg ctg ttc ccg ggt gtg gcg ctg ctt 109 Met Arg Leu Arg Arg Leu Ala Leu Phe Pro Gly Val Ala Leu Leu 1 5 10 15ctt gcc gcg gcc cgc ctc gcc gct gcc tcc gac gtg cta gaa ctc acg 157Leu Ala Ala Ala Arg Leu Ala Ala Ala Ser Asp Val Leu Glu Leu Thr 20 25 30gac gac aac ttc gag agt cgc atc tcc gac acg ggc tct gcg ggc ctc 205Asp Asp Asn Phe Glu Ser Arg Ile Ser Asp Thr Gly Ser Ala Gly Leu 35 40 45atg ctc gtc gag ttc ttc gct ccc tgg tgt gga cac tgc aag aga ctt 253Met Leu Val Glu Phe Phe Ala Pro Trp Cys Gly His Cys Lys Arg Leu 50 55 60gca cct gag tat gaa gct gca gct acc aga tta aaa gga ata gtc cca 301Ala Pro Glu Tyr Glu Ala Ala Ala Thr Arg Leu Lys Gly Ile Val Pro 65 70 75tta gca aag gtt gat tgc act gcc aac act aac acc tgt aat aaa tat 349Leu Ala Lys Val Asp Cys Thr Ala Asn Thr Asn Thr Cys Asn Lys Tyr80 85 90 95gga gtc agt gga tat cca acc ctg aag ata ttt aga gat ggt gaa gaa 397Gly Val Ser Gly Tyr Pro Thr Leu Lys Ile Phe Arg Asp Gly Glu Glu 100 105 110gca ggt gct tat gat gga cct agg act gct gat gga att gtc agc cac 445Ala Gly Ala Tyr Asp Gly Pro Arg Thr Ala Asp Gly Ile Val Ser His 115 120 125ttg aag aag cag gca gga cca gct tca gtg cct ctc agg act gag gaa 493Leu Lys Lys Gln Ala Gly Pro Ala Ser Val Pro Leu Arg Thr Glu Glu 130 135 140gaa ttt aag aaa ttc att agt gat aaa gat gcc tct ata gta ggt ttt 541Glu Phe Lys Lys Phe Ile Ser Asp Lys Asp Ala Ser Ile Val Gly Phe 145 150 155ttc gat gat tca ttc agt gag gct cac tcc gag ttc cta aaa gca gcc 589Phe Asp Asp Ser Phe Ser Glu Ala His Ser Glu Phe Leu Lys Ala Ala160 165 170 175agc aac ttg agg gat aac tac cga ttt gca cat acg aat gtt gag tct 637Ser Asn Leu Arg Asp Asn Tyr Arg Phe Ala His Thr Asn Val Glu Ser 180 185 190ctg gtg aac gag tat gat gat aat gga gag ggt atc atc tta ttt cgt 685Leu Val Asn Glu Tyr Asp Asp Asn Gly Glu Gly Ile Ile Leu Phe Arg 195 200 205cct tca cat ctc act aac aag ttt gag gac aag act gtg gca tat aca 733Pro Ser His Leu Thr Asn Lys Phe Glu Asp Lys Thr Val Ala Tyr Thr 210 215 220gag caa aaa atg acc agt ggc aaa att aaa aag ttt atc cag gaa aac 781Glu Gln Lys Met Thr Ser Gly Lys Ile Lys Lys Phe Ile Gln Glu Asn 225 230 235att ttt ggt atc tgc cct cac atg aca gaa gac aat aaa gat ttg ata 829Ile Phe Gly Ile Cys Pro His Met Thr Glu Asp Asn Lys Asp Leu Ile240 245 250 255cag ggc aag gac tta ctt att gct tac tat gat gtg gac tat gaa aag 877Gln Gly Lys Asp Leu Leu Ile Ala Tyr Tyr Asp Val Asp Tyr Glu Lys 260 265 270aac gct aaa ggt tcc aac tac tgg aga aac agg gta atg atg gtg gca 925Asn Ala Lys Gly Ser Asn Tyr Trp Arg Asn Arg Val Met Met Val Ala 275 280 285aag aaa ttc ctg gat gct ggg cac aaa ctc aac ttt gct gta gct agc 973Lys Lys Phe Leu Asp Ala Gly His Lys Leu Asn Phe Ala Val Ala Ser 290 295 300cgc aaa acc ttt agc cat gaa ctt tct gat ttt ggc ttg gag agc act 1021Arg Lys Thr Phe Ser His Glu Leu Ser Asp Phe Gly Leu Glu Ser Thr 305 310 315gct gga gag att cct gtt gtt gct atc aga act gct aaa gga gag aag 1069Ala Gly Glu Ile Pro Val Val Ala Ile Arg Thr Ala Lys Gly Glu Lys320 325 330 335ttt gtc atg cag gag gag ttc tcg cgt gat ggg aag gct ctg gag agg 1117Phe Val Met Gln Glu Glu Phe Ser Arg Asp Gly Lys Ala Leu Glu Arg 340 345 350ttc ctg cag gat tac ttt gat ggc aat ctg aag aga tac ctg aag tct 1165Phe Leu Gln Asp Tyr Phe Asp Gly Asn Leu Lys Arg Tyr Leu Lys Ser 355 360 365gaa cct atc cca gag agc aat gat ggg cct gtg aag gta gtg gta gca 1213Glu Pro Ile Pro Glu Ser Asn Asp Gly Pro Val Lys Val Val Val Ala 370 375 380gag aat ttt gat gaa ata gtg aat aat gaa aat aaa gat gtg ctg att 1261Glu Asn Phe Asp Glu Ile Val Asn Asn Glu Asn Lys Asp Val Leu Ile 385 390 395gaa ttt tat gcc cct tgg tgt ggt cat tgt aag aac ctg gag ccc aag 1309Glu Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Asn Leu Glu Pro Lys400 405 410 415tat aaa gaa ctt ggc gag aag ctc agc aaa gac cca aat atc gtc ata 1357Tyr Lys Glu Leu Gly Glu Lys Leu Ser Lys Asp Pro Asn Ile Val Ile 420 425 430gcc aag atg gat gcc aca gcc aat gat gtg cct tct cca tat gaa gtc 1405Ala Lys Met Asp Ala Thr Ala Asn Asp Val Pro Ser Pro Tyr Glu Val 435 440 445aga ggt ttt cct acc ata tac ttc tct cca gcc aac aag aag cta aat 1453Arg Gly Phe Pro Thr Ile Tyr Phe Ser Pro Ala Asn Lys Lys Leu Asn 450 455 460cca aag aaa tat gaa ggt ggc cgt gaa tta agt gat ttt att agc tat 1501Pro Lys Lys Tyr Glu Gly Gly Arg Glu Leu Ser Asp Phe Ile Ser Tyr 465 470 475cta caa aga gaa gct aca aac ccc cct gta att caa gaa gaa aaa ccc 1549Leu Gln Arg Glu Ala Thr Asn Pro Pro Val Ile Gln Glu Glu Lys Pro480 485 490 495aag aag aag aag aag gca cag gag gat ctc taa agcagtagcc aaacaccact 1602Lys Lys Lys Lys Lys Ala Gln Glu Asp Leu 500 505ttgtaaaagg actcttccat cagagatggg aaaaccattg gggaggacta ggacccatat 1662gggaattatt acctctcagg gccgagagtc taga 169612505PRTHomo sapiens 12Met Arg Leu Arg Arg Leu Ala Leu Phe Pro Gly Val Ala Leu Leu Leu1 5 10 15Ala Ala Ala Arg Leu Ala Ala Ala Ser Asp Val Leu Glu Leu Thr Asp 20 25 30Asp Asn Phe Glu Ser Arg Ile Ser Asp Thr Gly Ser Ala Gly Leu Met 35 40 45Leu Val Glu Phe Phe Ala Pro Trp Cys Gly His Cys Lys Arg Leu Ala 50 55 60Pro Glu Tyr Glu Ala Ala Ala Thr Arg Leu Lys Gly Ile Val Pro Leu65 70 75 80Ala Lys Val Asp Cys Thr Ala Asn Thr Asn Thr Cys Asn Lys Tyr Gly 85 90 95Val Ser Gly Tyr Pro Thr Leu Lys Ile Phe Arg Asp Gly Glu Glu Ala 100 105 110Gly Ala Tyr Asp Gly Pro Arg Thr Ala Asp Gly Ile Val Ser His Leu 115 120 125Lys Lys Gln Ala Gly Pro Ala Ser Val Pro Leu Arg Thr Glu Glu Glu 130 135 140Phe Lys Lys Phe Ile Ser Asp Lys Asp Ala Ser Ile Val Gly Phe Phe145 150 155 160Asp Asp Ser Phe Ser Glu Ala His Ser Glu Phe Leu Lys Ala Ala Ser 165 170 175Asn Leu Arg Asp Asn Tyr Arg Phe Ala His Thr Asn Val Glu Ser Leu 180 185 190Val Asn Glu Tyr Asp Asp Asn Gly Glu Gly Ile Ile Leu Phe Arg Pro 195 200 205Ser His Leu Thr Asn Lys Phe Glu Asp Lys Thr Val Ala Tyr Thr Glu 210 215 220Gln Lys Met Thr Ser Gly Lys Ile Lys Lys Phe Ile Gln Glu Asn Ile225 230 235 240Phe Gly Ile Cys Pro His Met Thr Glu Asp Asn Lys Asp Leu Ile Gln 245 250 255Gly Lys Asp Leu Leu Ile Ala Tyr Tyr Asp Val Asp Tyr Glu Lys Asn 260 265 270Ala Lys Gly Ser Asn Tyr Trp Arg Asn Arg Val Met Met Val Ala Lys 275 280 285Lys Phe Leu Asp Ala Gly His Lys Leu Asn Phe Ala Val Ala Ser Arg 290 295 300Lys Thr Phe Ser His Glu Leu Ser Asp Phe Gly Leu Glu Ser Thr Ala305 310 315 320Gly Glu Ile Pro Val Val Ala Ile Arg Thr Ala Lys Gly Glu Lys Phe 325 330 335Val Met Gln Glu Glu Phe Ser Arg Asp Gly Lys Ala Leu Glu Arg Phe 340 345 350Leu Gln Asp Tyr Phe Asp Gly Asn Leu Lys Arg Tyr Leu Lys Ser Glu 355 360 365Pro Ile Pro Glu Ser Asn Asp Gly Pro Val Lys Val Val Val Ala Glu 370 375 380Asn Phe Asp Glu Ile Val Asn Asn Glu Asn Lys Asp Val Leu Ile Glu385 390 395 400Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Asn Leu Glu Pro Lys Tyr 405 410 415Lys Glu Leu Gly Glu Lys Leu Ser Lys Asp Pro Asn Ile Val Ile Ala 420 425 430Lys Met Asp Ala Thr Ala Asn Asp Val Pro Ser Pro Tyr Glu Val Arg 435 440 445Gly Phe Pro Thr Ile Tyr Phe Ser Pro Ala Asn Lys Lys Leu Asn Pro 450 455 460Lys Lys Tyr Glu Gly Gly Arg Glu Leu Ser Asp Phe Ile Ser Tyr Leu465 470 475 480Gln Arg Glu Ala Thr Asn Pro Pro Val Ile Gln Glu Glu Lys Pro Lys 485 490 495Lys Lys Lys Lys Ala Gln Glu Asp Leu 500 505131926DNAHomo sapiensCDS(1)..(1926) 13atg gcc aaa gcc gcg gcg atc ggc atc gac ctg ggc acc acc tac tcc 48Met Ala Lys Ala Ala Ala Ile Gly Ile Asp Leu Gly Thr Thr Tyr Ser1 5 10 15tgc gtg ggg gtg ttc caa cac ggc aag gtg gag atc atc gcc aac gac 96Cys Val Gly Val Phe Gln His Gly Lys Val Glu Ile Ile Ala Asn Asp 20 25 30cag ggc aac cgc acc acc ccc agc tac gtg gcc ttc acg gac acc gag 144Gln Gly Asn Arg Thr Thr Pro Ser Tyr Val Ala Phe Thr Asp Thr Glu 35 40 45cgg ctc atc ggg gat gcg gcc aag aac cag gtg gcg ctg aac ccg cag 192Arg Leu Ile Gly Asp Ala Ala Lys Asn Gln Val Ala Leu Asn Pro Gln 50 55 60aac acc gtg ttt gac gcg aag cgg ctg atc ggc cgc aag ttc ggc gac 240Asn Thr Val Phe Asp Ala Lys Arg Leu Ile Gly Arg Lys Phe Gly Asp65 70 75 80ccg gtg gtg cag tcg gac atg aag cac tgg cct ttc cag gtg atc aac 288Pro Val Val Gln Ser Asp Met Lys His Trp Pro Phe Gln Val Ile Asn 85 90 95gac gga gac aag ccc aag gtg cag gtg agc tac aag ggg gag acc aag 336Asp Gly Asp Lys Pro Lys Val Gln Val Ser Tyr Lys Gly Glu Thr Lys 100 105 110gca ttc tac ccc gag gag atc tcg tcc atg gtg ctg acc aag atg aag 384Ala Phe Tyr Pro Glu Glu Ile Ser Ser Met Val Leu Thr Lys Met Lys 115 120 125gag atc gcc gag gcg tac ctg ggc tac ccg gtg acc aac gcg gtg atc 432Glu Ile Ala Glu Ala Tyr Leu Gly Tyr Pro Val Thr Asn Ala Val Ile 130 135 140acc gtg ccg gcc tac ttc aac gac tcg cag cgc cag gcc acc aag gat 480Thr Val Pro Ala Tyr Phe Asn Asp Ser Gln Arg Gln Ala Thr Lys Asp145 150 155 160gcg ggt gtg atc gcg ggg ctc aac gtg ctg cgg atc atc aac gag ccc 528Ala Gly Val Ile Ala Gly Leu Asn Val Leu Arg Ile Ile Asn Glu Pro 165 170 175acg gcc gcc gcc atc gcc tac ggc ctg gac aga acg ggc aag ggg gag 576Thr Ala Ala Ala Ile Ala Tyr Gly Leu Asp Arg Thr Gly Lys Gly Glu 180 185 190cgc aac gtg ctc atc ttt gac ctg ggc ggg ggc acc ttc gac gtg tcc 624Arg Asn Val Leu Ile Phe Asp Leu Gly Gly Gly Thr Phe Asp Val Ser 195 200 205atc ctg acg atc gac gac ggc atc ttc gag gtg aag gcc acg gcc ggg 672Ile Leu Thr Ile Asp Asp Gly Ile Phe Glu Val Lys Ala Thr Ala Gly 210 215 220gac acc cac ctg ggt ggg gag gac ttt gac aac agg ctg gtg aac cac 720Asp Thr His Leu Gly Gly Glu Asp Phe Asp Asn Arg Leu Val Asn His225 230 235 240ttc gtg gag gag ttc aag aga aaa cac aag aag gac atc agc cag aac 768Phe Val Glu Glu Phe Lys Arg Lys His Lys Lys Asp Ile Ser Gln Asn 245 250 255aag cga gcc gtg agg cgg ctg cgc acc gcc tgc gag agg gcc aag agg 816Lys Arg Ala Val Arg Arg Leu Arg Thr Ala Cys Glu Arg Ala Lys Arg 260 265 270acc ctg tcg tcc agc acc cag gcc agc ctg gag atc gac tcc ctg ttt 864Thr Leu Ser Ser Ser Thr Gln Ala Ser Leu Glu Ile Asp Ser Leu Phe 275 280 285gag ggc atc gac ttc tac acg tcc atc acc agg gcg agg ttc gag gag 912Glu Gly Ile Asp Phe Tyr Thr Ser Ile Thr Arg Ala Arg Phe Glu Glu 290 295 300ctg tgc tcc gac ctg ttc cga agc acc ctg gag ccc gtg gag aag gct 960Leu Cys Ser Asp Leu Phe Arg Ser Thr Leu Glu Pro Val Glu Lys Ala305 310 315 320ctg cgc gac gcc aag ctg gac aag gcc cag att cac gac ctg gtc ctg 1008Leu Arg Asp Ala Lys Leu Asp Lys Ala Gln Ile His Asp Leu Val Leu 325 330 335gtc ggg ggc tcc acc cgc atc ccc aag gtg cag aag ctg ctg cag gac 1056Val Gly Gly Ser Thr Arg Ile Pro Lys Val Gln Lys Leu Leu Gln Asp 340 345 350ttc ttc aac ggg cgc gac ctg aac aag agc atc aac ccc gac gag gct 1104Phe Phe Asn Gly Arg Asp Leu Asn Lys Ser Ile Asn Pro Asp Glu Ala 355 360 365gtg gcc tac ggg gcg gcg gtg cag gcg gcc atc ctg atg ggg gac aag 1152Val Ala Tyr Gly Ala Ala Val Gln Ala Ala Ile Leu Met Gly Asp Lys 370 375 380tcc gag aac gtg cag gac ctg ctg ctg ctg gac gtg gct ccc ctg tcg 1200Ser Glu Asn Val Gln Asp Leu Leu Leu Leu Asp Val Ala Pro Leu Ser385 390 395 400ctg ggg ctg gag acg gcc gga ggc gtg atg act gcc ctg atc aag cgc 1248Leu Gly Leu Glu Thr Ala Gly Gly Val Met Thr Ala Leu Ile Lys Arg 405 410 415aac tcc acc atc ccc acc aag cag acg cag atc ttc acc acc tac tcc 1296Asn Ser Thr Ile Pro Thr Lys Gln Thr Gln Ile Phe Thr Thr Tyr Ser 420 425 430gac aac caa ccc ggg gtg ctg atc cag gtg tac gag ggc gag agg gcc 1344Asp Asn Gln Pro Gly Val Leu Ile Gln Val Tyr Glu Gly Glu Arg Ala 435 440 445atg acg aaa gac aac aat ctg ttg ggg cgc ttc gag ctg agc ggc atc 1392Met Thr Lys Asp Asn Asn Leu Leu Gly Arg Phe Glu Leu Ser Gly Ile 450 455 460cct ccg gcc ccc agg ggc gtg ccc cag atc gag gtg acc ttc gac atc 1440Pro Pro Ala Pro Arg Gly Val Pro Gln Ile Glu Val Thr Phe Asp Ile465 470 475 480gat gcc aac ggc atc ctg aac gtc acg gcc acg gac aag agc acc ggc 1488Asp Ala Asn Gly Ile Leu Asn Val Thr Ala

Thr Asp Lys Ser Thr Gly 485 490 495aag gcc aac aag atc acc atc acc aac gac aag ggc cgc ctg agc aag 1536Lys Ala Asn Lys Ile Thr Ile Thr Asn Asp Lys Gly Arg Leu Ser Lys 500 505 510gag gag atc gag cgc atg gtg cag gag gcg gag aag tac aaa gcg gag 1584Glu Glu Ile Glu Arg Met Val Gln Glu Ala Glu Lys Tyr Lys Ala Glu 515 520 525gac gag gtg cag cgc gag agg gtg tca gcc aag aac gcc ctg gag tcc 1632Asp Glu Val Gln Arg Glu Arg Val Ser Ala Lys Asn Ala Leu Glu Ser 530 535 540tac gcc ttc aac atg aag agc gcc gtg gag gat gag ggg ctc aag ggc 1680Tyr Ala Phe Asn Met Lys Ser Ala Val Glu Asp Glu Gly Leu Lys Gly545 550 555 560aag atc agc gag gcc gac aag aag aag gtg ctg gac aag tgt caa gag 1728Lys Ile Ser Glu Ala Asp Lys Lys Lys Val Leu Asp Lys Cys Gln Glu 565 570 575gtc atc tcg tgg ctg gac gcc aac acc ttg gcc gag aag gac gag ttt 1776Val Ile Ser Trp Leu Asp Ala Asn Thr Leu Ala Glu Lys Asp Glu Phe 580 585 590gag cac aag agg aag gag ctg gag cag gtg tgt aac ccc atc atc agc 1824Glu His Lys Arg Lys Glu Leu Glu Gln Val Cys Asn Pro Ile Ile Ser 595 600 605gga ctg tac cag ggt gcc ggt ggt ccc ggg cct ggg ggc ttc ggg gct 1872Gly Leu Tyr Gln Gly Ala Gly Gly Pro Gly Pro Gly Gly Phe Gly Ala 610 615 620cag ggt ccc aag gga ggg tct ggg tca ggc ccc acc att gag gag gta 1920Gln Gly Pro Lys Gly Gly Ser Gly Ser Gly Pro Thr Ile Glu Glu Val625 630 635 640gat tag 1926Asp14641PRTHomo sapiens 14Met Ala Lys Ala Ala Ala Ile Gly Ile Asp Leu Gly Thr Thr Tyr Ser1 5 10 15Cys Val Gly Val Phe Gln His Gly Lys Val Glu Ile Ile Ala Asn Asp 20 25 30Gln Gly Asn Arg Thr Thr Pro Ser Tyr Val Ala Phe Thr Asp Thr Glu 35 40 45Arg Leu Ile Gly Asp Ala Ala Lys Asn Gln Val Ala Leu Asn Pro Gln 50 55 60Asn Thr Val Phe Asp Ala Lys Arg Leu Ile Gly Arg Lys Phe Gly Asp65 70 75 80Pro Val Val Gln Ser Asp Met Lys His Trp Pro Phe Gln Val Ile Asn 85 90 95Asp Gly Asp Lys Pro Lys Val Gln Val Ser Tyr Lys Gly Glu Thr Lys 100 105 110Ala Phe Tyr Pro Glu Glu Ile Ser Ser Met Val Leu Thr Lys Met Lys 115 120 125Glu Ile Ala Glu Ala Tyr Leu Gly Tyr Pro Val Thr Asn Ala Val Ile 130 135 140Thr Val Pro Ala Tyr Phe Asn Asp Ser Gln Arg Gln Ala Thr Lys Asp145 150 155 160Ala Gly Val Ile Ala Gly Leu Asn Val Leu Arg Ile Ile Asn Glu Pro 165 170 175Thr Ala Ala Ala Ile Ala Tyr Gly Leu Asp Arg Thr Gly Lys Gly Glu 180 185 190Arg Asn Val Leu Ile Phe Asp Leu Gly Gly Gly Thr Phe Asp Val Ser 195 200 205Ile Leu Thr Ile Asp Asp Gly Ile Phe Glu Val Lys Ala Thr Ala Gly 210 215 220Asp Thr His Leu Gly Gly Glu Asp Phe Asp Asn Arg Leu Val Asn His225 230 235 240Phe Val Glu Glu Phe Lys Arg Lys His Lys Lys Asp Ile Ser Gln Asn 245 250 255Lys Arg Ala Val Arg Arg Leu Arg Thr Ala Cys Glu Arg Ala Lys Arg 260 265 270Thr Leu Ser Ser Ser Thr Gln Ala Ser Leu Glu Ile Asp Ser Leu Phe 275 280 285Glu Gly Ile Asp Phe Tyr Thr Ser Ile Thr Arg Ala Arg Phe Glu Glu 290 295 300Leu Cys Ser Asp Leu Phe Arg Ser Thr Leu Glu Pro Val Glu Lys Ala305 310 315 320Leu Arg Asp Ala Lys Leu Asp Lys Ala Gln Ile His Asp Leu Val Leu 325 330 335Val Gly Gly Ser Thr Arg Ile Pro Lys Val Gln Lys Leu Leu Gln Asp 340 345 350Phe Phe Asn Gly Arg Asp Leu Asn Lys Ser Ile Asn Pro Asp Glu Ala 355 360 365Val Ala Tyr Gly Ala Ala Val Gln Ala Ala Ile Leu Met Gly Asp Lys 370 375 380Ser Glu Asn Val Gln Asp Leu Leu Leu Leu Asp Val Ala Pro Leu Ser385 390 395 400Leu Gly Leu Glu Thr Ala Gly Gly Val Met Thr Ala Leu Ile Lys Arg 405 410 415Asn Ser Thr Ile Pro Thr Lys Gln Thr Gln Ile Phe Thr Thr Tyr Ser 420 425 430Asp Asn Gln Pro Gly Val Leu Ile Gln Val Tyr Glu Gly Glu Arg Ala 435 440 445Met Thr Lys Asp Asn Asn Leu Leu Gly Arg Phe Glu Leu Ser Gly Ile 450 455 460Pro Pro Ala Pro Arg Gly Val Pro Gln Ile Glu Val Thr Phe Asp Ile465 470 475 480Asp Ala Asn Gly Ile Leu Asn Val Thr Ala Thr Asp Lys Ser Thr Gly 485 490 495Lys Ala Asn Lys Ile Thr Ile Thr Asn Asp Lys Gly Arg Leu Ser Lys 500 505 510Glu Glu Ile Glu Arg Met Val Gln Glu Ala Glu Lys Tyr Lys Ala Glu 515 520 525Asp Glu Val Gln Arg Glu Arg Val Ser Ala Lys Asn Ala Leu Glu Ser 530 535 540Tyr Ala Phe Asn Met Lys Ser Ala Val Glu Asp Glu Gly Leu Lys Gly545 550 555 560Lys Ile Ser Glu Ala Asp Lys Lys Lys Val Leu Asp Lys Cys Gln Glu 565 570 575Val Ile Ser Trp Leu Asp Ala Asn Thr Leu Ala Glu Lys Asp Glu Phe 580 585 590Glu His Lys Arg Lys Glu Leu Glu Gln Val Cys Asn Pro Ile Ile Ser 595 600 605Gly Leu Tyr Gln Gly Ala Gly Gly Pro Gly Pro Gly Gly Phe Gly Ala 610 615 620Gln Gly Pro Lys Gly Gly Ser Gly Ser Gly Pro Thr Ile Glu Glu Val625 630 635 640Asp151023DNAHomo sapiensCDS(1)..(1023) 15atg ggt aaa gac tac tac cag acg ttg ggc ctg gcc cgc ggc gcg tcg 48Met Gly Lys Asp Tyr Tyr Gln Thr Leu Gly Leu Ala Arg Gly Ala Ser1 5 10 15gac gag gag atc aag cgg gcc tac cgc cgc cag gcg ctg cgc tac cac 96Asp Glu Glu Ile Lys Arg Ala Tyr Arg Arg Gln Ala Leu Arg Tyr His 20 25 30ccg gac aag aac aag gag ccc ggc gcc gag gag aag ttc aag gag atc 144Pro Asp Lys Asn Lys Glu Pro Gly Ala Glu Glu Lys Phe Lys Glu Ile 35 40 45gct gag gcc tac gac gtg ctc agc gac ccg cgc aag cgc gag atc ttc 192Ala Glu Ala Tyr Asp Val Leu Ser Asp Pro Arg Lys Arg Glu Ile Phe 50 55 60gac cgc tac ggg gag gaa ggc cta aag ggg agt ggc ccc agt ggc ggt 240Asp Arg Tyr Gly Glu Glu Gly Leu Lys Gly Ser Gly Pro Ser Gly Gly65 70 75 80agc ggc ggt ggt gcc aat ggt acc tct ttc agc tac aca ttc cat gga 288Ser Gly Gly Gly Ala Asn Gly Thr Ser Phe Ser Tyr Thr Phe His Gly 85 90 95gac cct cat gcc atg ttt gct gag ttc ttc ggt ggc aga aat ccc ttt 336Asp Pro His Ala Met Phe Ala Glu Phe Phe Gly Gly Arg Asn Pro Phe 100 105 110gac acc ttt ttt ggg cag cgg aac ggg gag gaa ggc atg gac att gat 384Asp Thr Phe Phe Gly Gln Arg Asn Gly Glu Glu Gly Met Asp Ile Asp 115 120 125gac cca ttc tct ggc ttc cct atg ggc atg ggt ggc ttc acc aac gtg 432Asp Pro Phe Ser Gly Phe Pro Met Gly Met Gly Gly Phe Thr Asn Val 130 135 140aac ttt ggc cgc tcc cgc tct gcc caa gag ccc gcc cga aag aag caa 480Asn Phe Gly Arg Ser Arg Ser Ala Gln Glu Pro Ala Arg Lys Lys Gln145 150 155 160gat ccc cca gtc acc cac gac ctt cga gtc tcc ctt gaa gag atc tac 528Asp Pro Pro Val Thr His Asp Leu Arg Val Ser Leu Glu Glu Ile Tyr 165 170 175agc ggc tgt acc aag aag atg aaa atc tcc cac aag cgg cta aac ccc 576Ser Gly Cys Thr Lys Lys Met Lys Ile Ser His Lys Arg Leu Asn Pro 180 185 190gac gga aag agc att cga aac gaa gac aaa ata ttg acc atc gaa gtg 624Asp Gly Lys Ser Ile Arg Asn Glu Asp Lys Ile Leu Thr Ile Glu Val 195 200 205aag aag ggg tgg aaa gaa gga acc aaa atc act ttc ccc aag gaa gga 672Lys Lys Gly Trp Lys Glu Gly Thr Lys Ile Thr Phe Pro Lys Glu Gly 210 215 220gac cag acc tcc aac aac att cca gct gat atc gtc ttt gtt tta aag 720Asp Gln Thr Ser Asn Asn Ile Pro Ala Asp Ile Val Phe Val Leu Lys225 230 235 240gac aag ccc cac aat atc ttt aag aga gat ggc tct gat gtc att tat 768Asp Lys Pro His Asn Ile Phe Lys Arg Asp Gly Ser Asp Val Ile Tyr 245 250 255cct gcc agg atc agc ctc cgg gag gct ctg tgt ggc tgc aca gtg aac 816Pro Ala Arg Ile Ser Leu Arg Glu Ala Leu Cys Gly Cys Thr Val Asn 260 265 270gtc ccc act ctg gac ggc agg acg ata ccc gtc gta ttc aaa gat gtt 864Val Pro Thr Leu Asp Gly Arg Thr Ile Pro Val Val Phe Lys Asp Val 275 280 285atc agg cct ggc atg cgg cga aaa gtt cct gga gaa ggc ctc ccc ctc 912Ile Arg Pro Gly Met Arg Arg Lys Val Pro Gly Glu Gly Leu Pro Leu 290 295 300ccc aaa aca ccc gag aaa cgt ggg gac ctc att att gag ttt gaa gtg 960Pro Lys Thr Pro Glu Lys Arg Gly Asp Leu Ile Ile Glu Phe Glu Val305 310 315 320atc ttc ccc gaa agg att ccc cag aca tca aga acc gta ctt gag cag 1008Ile Phe Pro Glu Arg Ile Pro Gln Thr Ser Arg Thr Val Leu Glu Gln 325 330 335gtt ctt cca ata tag 1023Val Leu Pro Ile 34016340PRTHomo sapiens 16Met Gly Lys Asp Tyr Tyr Gln Thr Leu Gly Leu Ala Arg Gly Ala Ser1 5 10 15Asp Glu Glu Ile Lys Arg Ala Tyr Arg Arg Gln Ala Leu Arg Tyr His 20 25 30Pro Asp Lys Asn Lys Glu Pro Gly Ala Glu Glu Lys Phe Lys Glu Ile 35 40 45Ala Glu Ala Tyr Asp Val Leu Ser Asp Pro Arg Lys Arg Glu Ile Phe 50 55 60Asp Arg Tyr Gly Glu Glu Gly Leu Lys Gly Ser Gly Pro Ser Gly Gly65 70 75 80Ser Gly Gly Gly Ala Asn Gly Thr Ser Phe Ser Tyr Thr Phe His Gly 85 90 95Asp Pro His Ala Met Phe Ala Glu Phe Phe Gly Gly Arg Asn Pro Phe 100 105 110Asp Thr Phe Phe Gly Gln Arg Asn Gly Glu Glu Gly Met Asp Ile Asp 115 120 125Asp Pro Phe Ser Gly Phe Pro Met Gly Met Gly Gly Phe Thr Asn Val 130 135 140Asn Phe Gly Arg Ser Arg Ser Ala Gln Glu Pro Ala Arg Lys Lys Gln145 150 155 160Asp Pro Pro Val Thr His Asp Leu Arg Val Ser Leu Glu Glu Ile Tyr 165 170 175Ser Gly Cys Thr Lys Lys Met Lys Ile Ser His Lys Arg Leu Asn Pro 180 185 190Asp Gly Lys Ser Ile Arg Asn Glu Asp Lys Ile Leu Thr Ile Glu Val 195 200 205Lys Lys Gly Trp Lys Glu Gly Thr Lys Ile Thr Phe Pro Lys Glu Gly 210 215 220Asp Gln Thr Ser Asn Asn Ile Pro Ala Asp Ile Val Phe Val Leu Lys225 230 235 240Asp Lys Pro His Asn Ile Phe Lys Arg Asp Gly Ser Asp Val Ile Tyr 245 250 255Pro Ala Arg Ile Ser Leu Arg Glu Ala Leu Cys Gly Cys Thr Val Asn 260 265 270Val Pro Thr Leu Asp Gly Arg Thr Ile Pro Val Val Phe Lys Asp Val 275 280 285Ile Arg Pro Gly Met Arg Arg Lys Val Pro Gly Glu Gly Leu Pro Leu 290 295 300Pro Lys Thr Pro Glu Lys Arg Gly Asp Leu Ile Ile Glu Phe Glu Val305 310 315 320Ile Phe Pro Glu Arg Ile Pro Gln Thr Ser Arg Thr Val Leu Glu Gln 325 330 335Val Leu Pro Ile 340171122DNAHomo sapiensCDS(1)..(1122) 17atg acc acc tca gca agt tcc cac tta aat aaa ggc atc aag cag gtg 48Met Thr Thr Ser Ala Ser Ser His Leu Asn Lys Gly Ile Lys Gln Val1 5 10 15tac atg tcc ctg cct cag ggt gag aaa gtc cag gcc atg tat atc tgg 96Tyr Met Ser Leu Pro Gln Gly Glu Lys Val Gln Ala Met Tyr Ile Trp 20 25 30atc gat ggt act gga gaa gga ctg cgc tgc aag acc cgg acc ctg gac 144Ile Asp Gly Thr Gly Glu Gly Leu Arg Cys Lys Thr Arg Thr Leu Asp 35 40 45agt gag ccc aag tgt gtg gaa gag ttg cct gag tgg aat ttc gat ggc 192Ser Glu Pro Lys Cys Val Glu Glu Leu Pro Glu Trp Asn Phe Asp Gly 50 55 60tcc agt act tta cag tct gag ggt tcc aac agt gac atg tat ctc gtg 240Ser Ser Thr Leu Gln Ser Glu Gly Ser Asn Ser Asp Met Tyr Leu Val65 70 75 80cct gct gcc atg ttt cgg gac ccc ttc cgt aag gac cct aac aag ctg 288Pro Ala Ala Met Phe Arg Asp Pro Phe Arg Lys Asp Pro Asn Lys Leu 85 90 95gtg tta tgt gaa gtt ttc aag tac aat cga agg cct gca gag acc aat 336Val Leu Cys Glu Val Phe Lys Tyr Asn Arg Arg Pro Ala Glu Thr Asn 100 105 110ttg agg cac acc tgt aaa cgg ata atg gac atg gtg agc aac cag cac 384Leu Arg His Thr Cys Lys Arg Ile Met Asp Met Val Ser Asn Gln His 115 120 125ccc tgg ttt ggc atg gag cag gag tat acc ctc atg ggg aca gat ggg 432Pro Trp Phe Gly Met Glu Gln Glu Tyr Thr Leu Met Gly Thr Asp Gly 130 135 140cac ccc ttt ggt tgg cct tcc aac ggc ttc cca ggg ccc cag ggt cca 480His Pro Phe Gly Trp Pro Ser Asn Gly Phe Pro Gly Pro Gln Gly Pro145 150 155 160tat tac tgt ggt gtg gga gca gac aga gcc tat ggc agg gac atc gtg 528Tyr Tyr Cys Gly Val Gly Ala Asp Arg Ala Tyr Gly Arg Asp Ile Val 165 170 175gag gcc cat tac cgg gcc tgc ttg tat gct gga gtc aag att gcg ggg 576Glu Ala His Tyr Arg Ala Cys Leu Tyr Ala Gly Val Lys Ile Ala Gly 180 185 190act aat gcc gag gtc atg cct gcc cag tgg gaa ttt cag att gga cct 624Thr Asn Ala Glu Val Met Pro Ala Gln Trp Glu Phe Gln Ile Gly Pro 195 200 205tgt gaa gga atc agc atg gga gat cat ctc tgg gtg gcc cgt ttc atc 672Cys Glu Gly Ile Ser Met Gly Asp His Leu Trp Val Ala Arg Phe Ile 210 215 220ttg cat cgt gtg tgt gaa gac ttt gga gtg ata gca acc ttt gat cct 720Leu His Arg Val Cys Glu Asp Phe Gly Val Ile Ala Thr Phe Asp Pro225 230 235 240aag ccc att cct ggg aac tgg aat ggt gca ggc tgc cat acc aac ttc 768Lys Pro Ile Pro Gly Asn Trp Asn Gly Ala Gly Cys His Thr Asn Phe 245 250 255agc acc aag gcc atg cgg gag gag aat ggt ctg aag tac atc gag gag 816Ser Thr Lys Ala Met Arg Glu Glu Asn Gly Leu Lys Tyr Ile Glu Glu 260 265 270gcc att gag aaa cta agc aag cgg cac cag tac cac atc cgt gcc tat 864Ala Ile Glu Lys Leu Ser Lys Arg His Gln Tyr His Ile Arg Ala Tyr 275 280 285gat ccc aag gga ggc ctg gac aat gcc cga cgt cta act gga ttc cat 912Asp Pro Lys Gly Gly Leu Asp Asn Ala Arg Arg Leu Thr Gly Phe His 290 295 300gaa acc tcc aac atc aac gac ttt tct gct ggt gta gcc aat cgt agc 960Glu Thr Ser Asn Ile Asn Asp Phe Ser Ala Gly Val Ala Asn Arg Ser305 310 315 320gcc agc ata cgc att ccc cgg act gtt ggc cag gag aag aag ggt tac 1008Ala Ser Ile Arg Ile Pro Arg Thr Val Gly Gln Glu Lys Lys Gly Tyr 325 330 335ttt gaa gat cgt cgc ccc tct gcc aac tgc gac ccc ttt tcg gtg aca 1056Phe Glu Asp Arg Arg Pro Ser Ala Asn Cys Asp Pro Phe Ser Val Thr 340 345 350gaa gcc ctc atc cgc acg tgt ctt ctc aat gaa acc ggc gat gag ccc 1104Glu Ala Leu Ile Arg Thr Cys Leu Leu Asn Glu Thr Gly Asp Glu Pro 355 360 365ttc cag tac aaa aat taa 1122Phe Gln Tyr Lys Asn 37018373PRTHomo sapiens 18Met Thr Thr Ser Ala Ser Ser His Leu Asn Lys Gly Ile Lys Gln Val1 5 10 15Tyr Met Ser Leu Pro Gln Gly Glu Lys Val Gln Ala Met Tyr Ile Trp 20 25 30Ile Asp Gly Thr Gly Glu Gly Leu Arg Cys Lys Thr Arg Thr Leu Asp 35 40 45Ser Glu Pro Lys Cys Val Glu Glu Leu Pro Glu Trp Asn Phe Asp Gly 50 55 60Ser Ser Thr Leu Gln Ser

Glu Gly Ser Asn Ser Asp Met Tyr Leu Val65 70 75 80Pro Ala Ala Met Phe Arg Asp Pro Phe Arg Lys Asp Pro Asn Lys Leu 85 90 95Val Leu Cys Glu Val Phe Lys Tyr Asn Arg Arg Pro Ala Glu Thr Asn 100 105 110Leu Arg His Thr Cys Lys Arg Ile Met Asp Met Val Ser Asn Gln His 115 120 125Pro Trp Phe Gly Met Glu Gln Glu Tyr Thr Leu Met Gly Thr Asp Gly 130 135 140His Pro Phe Gly Trp Pro Ser Asn Gly Phe Pro Gly Pro Gln Gly Pro145 150 155 160Tyr Tyr Cys Gly Val Gly Ala Asp Arg Ala Tyr Gly Arg Asp Ile Val 165 170 175Glu Ala His Tyr Arg Ala Cys Leu Tyr Ala Gly Val Lys Ile Ala Gly 180 185 190Thr Asn Ala Glu Val Met Pro Ala Gln Trp Glu Phe Gln Ile Gly Pro 195 200 205Cys Glu Gly Ile Ser Met Gly Asp His Leu Trp Val Ala Arg Phe Ile 210 215 220Leu His Arg Val Cys Glu Asp Phe Gly Val Ile Ala Thr Phe Asp Pro225 230 235 240Lys Pro Ile Pro Gly Asn Trp Asn Gly Ala Gly Cys His Thr Asn Phe 245 250 255Ser Thr Lys Ala Met Arg Glu Glu Asn Gly Leu Lys Tyr Ile Glu Glu 260 265 270Ala Ile Glu Lys Leu Ser Lys Arg His Gln Tyr His Ile Arg Ala Tyr 275 280 285Asp Pro Lys Gly Gly Leu Asp Asn Ala Arg Arg Leu Thr Gly Phe His 290 295 300Glu Thr Ser Asn Ile Asn Asp Phe Ser Ala Gly Val Ala Asn Arg Ser305 310 315 320Ala Ser Ile Arg Ile Pro Arg Thr Val Gly Gln Glu Lys Lys Gly Tyr 325 330 335Phe Glu Asp Arg Arg Pro Ser Ala Asn Cys Asp Pro Phe Ser Val Thr 340 345 350Glu Ala Leu Ile Arg Thr Cys Leu Leu Asn Glu Thr Gly Asp Glu Pro 355 360 365Phe Gln Tyr Lys Asn 37019170PRTHomo sapiens 19Ala Asp Arg Glu Arg Ser Ile His Asp Phe Cys Leu Val Ser Lys Val1 5 10 15Val Gly Arg Cys Arg Ala Ser Met Pro Arg Trp Trp Tyr Asn Val Thr 20 25 30Asp Gly Ser Cys Gln Leu Phe Val Tyr Gly Gly Cys Asp Gly Asn Ser 35 40 45Asn Asn Tyr Leu Thr Lys Glu Glu Cys Leu Lys Lys Cys Ala Thr Val 50 55 60Thr Glu Asn Ala Thr Gly Asp Leu Ala Thr Ser Arg Asn Ala Ala Asp65 70 75 80Ser Ser Val Pro Ser Ala Pro Arg Arg Gln Asp Ser Glu Asp His Ser 85 90 95Ser Asp Met Phe Asn Tyr Glu Glu Tyr Cys Thr Ala Asn Ala Val Thr 100 105 110Gly Pro Cys Arg Ala Ser Phe Pro Arg Trp Tyr Phe Asp Val Glu Arg 115 120 125Asn Ser Cys Asn Asn Phe Ile Tyr Gly Gly Cys Arg Gly Asn Lys Asn 130 135 140Ser Tyr Arg Ser Glu Glu Ala Cys Met Leu Arg Cys Phe Arg Gln Gln145 150 155 160Glu Asn Pro Pro Leu Pro Leu Gly Ser Lys 165 1702020DNAArtificial sequencesynthetic oligonucleotide 20agggaaccgc atggccaaag 202125DNAArtificial Sequencesynthetic oligonucleotide 21gaaaggcccc taatctacct cctca 25223PRTArtificial sequencesynthetic peptide 22Pro Phe Xaa1

Claims

1. A mammalian host cell for enhanced expression of a recombinant protein product, said mammalian cell having genetic material coding for expression of said recombinant protein product and transformed with at least one expression vector comprising DNA encoding calnexin as a chaperone protein.

2-71. (canceled)

72. The mammalian host cell according to claim 1, wherein the recombinant protein product is secreted.

73. The mammalian host cell according to claim 72, wherein the genetic material coding for the expression of said recombinant protein product is integrated into host cell DNA.

74. The mammalian host cell according to claim 73, further transformed with an expression vector comprising DNA enclosing a glutamine synthetase protein.

75. The mammalian host cell according to claim 73, wherein said recombinant protein is bikunin or fragment thereof.

76. The mammalian host cell according to claim 73, wherein said recombinant protein is Factor VIII or fragment thereof.

Images